  
 
 
IONIS  PHARMACEUTICALS, INC. 
 
 
ISIS  396443-CS3A  
 
A Study to Assess the Efficacy, Safety, Tolerability , and 
Pharmacokinetics of Multiple Doses of Nusinersen ( ISIS  396443) 
Delivered Intrathecally to Patients with Infantile -Onset Spinal 
Muscular Atrophy  
 
Protocol Amendment 6 – 25 January 2016  
 
 
 
 
 
Sponsor:  
Ionis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad, CA  92010 

ISIS 396443-CS3A 
Protocol CONFIDENTIAL 
ISIS 396443-CS3A Amendment 6 
25 January 2016 
A Study to Assess the Efficacy, Safety, Tolerability, and 
Pharmacokinetics of Multiple Doses of Nusinersen (ISIS 396443) 
Delivered Intrathecally to Patients with Infantile-Onset Spinal 
Muscular Atrophy 
Protocol Amendment 6-25 January 2016 
Protocol History: 
Original Protocol: 
Protocol Amendment 1: 
Protocol Amendment 2: 
Protocol Amendment 3: 
Protocol Amendment 4: 
Protocol Amendment 5: 
Sponsor: 
Ionis Pharmaceuticals, Inc. 
2855 Gazelle Court 
Carlsbad, CA 92010 4 March 2013 
14 August 2013 
18 January 2014 
14 March 2014 
19 May 2014 
29 May 2015 
2 
PPD
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
3   
ISIS  396443  
Ionis Protocol Number ISIS  396443- CS3A 
Protocol Amendment 6  
 
Clinical Phase:   2 
A Study to Assess the Efficacy, Safety, Tolerability , and 
Pharmacokinetics of Multiple Doses of Nusinersen ( ISIS  396443) 
Delivered Intrathecally to Patients with Infantile -Onset Spinal 
Muscular Atrophy  
 
Trial Sponsor:  Ionis  Pharmaceuticals,  Inc. 
2855 Gazelle Court  
Carlsbad, CA  92010  
Phone:  + 01 760 931 9200  
Fax: + 01 760 603 2700  
Key Sponsor Contact:   
 
 
Phone:  +  
Fax: +  
Date:  25 January  2016 
 
 
Confidentiality Statement 
This document contains confidential information of Ionis Pharmaceuticals, Inc.  that must not be 
disclosed to anyone other than the recipient study staff and members of the institutional review 
board or authorized r egulatory agencies.  This information cannot be used for any purpose other 
than the evaluation or conduct of the clinical investigation without the prior written consent of 
Ionis Pharmaceuticals, Inc.  
PPD
PPD
PPD
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
4  Protocol  Signature Page 
 
Protocol Number:  ISIS 396443- CS3A 
Protocol Title:  A Study to Assess the Efficacy, Safety, Tolerability , and Pharmacokinetics 
of Multiple Doses of Nusinersen ( ISIS 396443) Delivered Intrathecally to 
Patients with Infantile -Onset Spinal Muscular Atrophy 
Amendment:  Amendment 6 
Date:  25 January 2016 
 
I hereby acknowledge that I have read and understand the attached clinical protocol, entitled “ A 
Study to Assess the Efficacy, Safety, Tolerability , and Pharmacokinetics  of Multiple Doses of 
Nusinersen ( ISIS 396443) Delivered Intrathecally to Patients with Infantile -Onset Spinal 
Muscular Atrophy”, dated 25 January 2016, and agree to conduct the study as described herein. 
I agree to comply with the International Conference on Harmonization  Tripartite Guideline on 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc.  
 
 
 
   
Investigator’s Signature  
   
Investigator’s Name (please print)   Date (DD Month YYYY)  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENT .......................................................................................................9  
PROTOCOL SYNOPSIS  ............................................................................................................10  
STUDY GLOSSARY ...................................................................................................................14  
1. OBJECTIVES  .....................................................................................................................16  
1.1 Primary Objective  .....................................................................................................16  
1.2 Secondary Objectives ................................................................................................16  
2. BACKGROUND AND RATIO NALE  ..............................................................................16  
2.1 Spinal Muscula r Atrophy  ..........................................................................................16  
2.2 Therapeutic Rationale  ...............................................................................................17  
2.3 ISIS 396443 ..............................................................................................................18  
2.3.1  Mechanism of Action  ...............................................................................18  
2.3.2  Chemistry  .................................................................................................18  
2.3.3  Preclinical Experience  ..............................................................................18  
2.3.4  Clinical Experience ..................................................................................19  
2.4 Rationale for Dose and Schedule of Administration ................................................20  
3. EXPERIMENTAL PLAN ..................................................................................................21  
3.1 Study Design  .............................................................................................................21  
3.2 Number of Study Centers..........................................................................................21  
3.3 Number of Subjects...................................................................................................21  
3.4 Overall Study Duration and Follow-up.....................................................................21  
3.4.1  Screening  ..................................................................................................22  
3.4.2  Treatment  ..................................................................................................22  
3.4.3  Post- Treatment Follow -up ........................................................................22  
3.5 End of Study .............................................................................................................22  
3.6 Safety Monitoring and Dose Escalation  ...................................................................22  
3.7 Dose Limiting Toxicity  .............................................................................................23  
4. SUBJECT ENROLLMENT ...............................................................................................23  
4.1 Screening ...................................................................................................................23  
4.2 Registration ...............................................................................................................23  
4.3 Replacement of Subjects  ...........................................................................................24  
5. SUBJECT ELIGIBILITY  ..................................................................................................24  
5.1 Inclusion Criteria  ......................................................................................................24  
5.2 Exclusion Criteria  .....................................................................................................25  
6. STUDY PROCEDURES  ....................................................................................................25  
6.1 Study Schedule..........................................................................................................25  
6.2 Study Assessments  ....................................................................................................25  
6.2.1  Collection of CSF .....................................................................................25  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
6  6.2.2  Laboratory Analytes  .................................................................................26  
6.2.3  Neurological Examinations as Assessed by the Hammersmith Infant 
Neurological Examination (HINE)  ..........................................................26  
6.2.4  Pharmacokinetics Specimen Collection  ...................................................26  
6.2.5  Children’s Hospital of Philadelphia Infant Test for Neuromuscular Disease (CHOP  INTEND)  .......................................................................26
 
6.2.6  Hammersmith Functional Motor Scale – Expanded ................................27  
6.2.7  Compound Muscle Action Potential ........................................................27  
6.2.8  Growth Parameters  ...................................................................................27  
6.2.9  Ventilation Use  .........................................................................................27  
6.2.10  Phone Assessments ...................................................................................27  
6.2.11  Safety Evaluations  ....................................................................................27  
7. STUDY DRUG  ....................................................................................................................28  
7.1 Study Drug  ................................................................................................................28  
7.1.1  Two-Vial Configuration (ISIS 396443 and Diluent) Description ............28  
7.1.2  Ready -To-Use Vial Configuration Description  .......................................29  
7.2 Packaging and Labeling  ............................................................................................29  
7.3 Study Drug Accountability .......................................................................................29  
8. TREATMENT OF SUBJECTS .........................................................................................29  
8.1 Study Drug Administration  .......................................................................................29  
8.2 Other Protocol- Required Drugs  ................................................................................31  
8.3 Other Protocol- Required Procedures  ........................................................................31  
8.4 Treatment Precautions  ..............................................................................................31  
8.5 Safety Monitoring Rules ...........................................................................................31  
8.6 Stopping Rules ..........................................................................................................31  
8.7 Adjustment of Dose and/or Treatment Schedule ......................................................31  
8.8 Discontinuation of Study Treatment .........................................................................31  
8.9 Withdrawal of Subjects from the Study ....................................................................31  
8.10  Concomitant Therapy and Procedures ......................................................................32  
8.10.1  Concomitant Therapy ...............................................................................32  
8.10.2  Concomitant Procedures ...........................................................................33  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................33  
9.1 Sponsor Review of Safety Information.....................................................................33  
9.2 Regulatory Requirements ..........................................................................................33  
9.3 Definitions .................................................................................................................33  
9.3.1  Adverse Event  ..........................................................................................33  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ................................33  
9.3.3  Serious Adverse Event (SAE) ..................................................................33  
9.4 Monitoring and Recording Adverse Events ..............................................................34  
9.4.1  Serious Adverse Events ............................................................................34  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
7  9.4.2  Non-Serious Adverse Events ....................................................................35  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ......................35  
9.4.3.1  Relationship to the Study Drug  ...................................................35  
9.4.3.2  Severity  .......................................................................................35  
9.4.3.3  Action Taken with Study Drug ...................................................36  
9.4.3.4  Treatment Given for Adverse Event  ...........................................36  
9.4.3.5  Outcome of the Adverse Event ...................................................36  
9.5 Procedures for Handling Special Situations .............................................................36  
9.5.1  Abnormalities of Laboratory Tests ...........................................................36  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments 37 
9.5.3  Dosing Errors ...........................................................................................37  
10. STATISTICAL CONSIDERATIONS  ..............................................................................37  
10.1  Study Endpoints  ........................................................................................................37  
10.1.1  Primary Endpoint .....................................................................................37  
10.1.2  Secondary Endpoints ................................................................................38  
10.1.3  Exploratory Endpoints ..............................................................................38  
10.2  Sample Size Considerations ......................................................................................38  
10.3  Populations ................................................................................................................39  
10.4  Interim Analysis  ........................................................................................................39  
10.5  Planned Methods of Analysis ...................................................................................39  
10.5.1  Demographic and Baseline Characteristics  ..............................................39  
10.5.2  Efficacy Analysis  .....................................................................................39  
10.5.3  Safety and Pharmacokinetic Analysis  ......................................................39  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .................................................40  
11.1  Informed Consent......................................................................................................40  
11.2  Ethical Conduct of the Study ....................................................................................40  
11.3  Institutional Review Board/Research Ethics Board  ..................................................41  
11.4  Subject Confidentiality  .............................................................................................41  
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  ....................................................41  
12.1  Protocol Amendments ...............................................................................................41  
12.2  Study Termination  ....................................................................................................42  
12.3  Study Documentation and Storage ............................................................................42  
12.4  Study Monitoring ......................................................................................................42  
12.5  Language  ...................................................................................................................43  
12.6  Compensation for Injury ...........................................................................................43  
13. REFERENCES  ....................................................................................................................44  
14. APPE NDICES  .....................................................................................................................46  
Appendix A  Schedule of Procedures .....................................................................47  
Appendix B  Laboratory Analytes  .........................................................................52  
Appendix C  Pharmacokinetic Sampling Schedule................................................54  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
8  TABLE OF TABLES 
Page 
Table 1  Study Drug Characteristics  ................................................................................... 28  
Table 2  Study Drug Characteristics:  Ready -To-Use Vial Configuration  ......................... 29  
Table 3  ISIS 396443 Dose Equivalents and Concentration During the ‘Loading’ 
Dosing Treatment Period  ...................................................................................... 30  
Table 4  ISIS 396443 Dose Equivalent and Concentration During the 
‘Maintenance’ Dosing Treatment Period  .............................................................. 30  
Table 5  ISIS 396443 Dose Volume to be Injected ............................................................. 30  
 
 
TABLE OF FIGURES 
Page 
Figure 1  ASO Therapeutic Approach for Treatment of SMA  ............................................. 17  
 
  
ISIS 396443-CS3A CONFIDENTIAL Amendment 6
Protocol 25 January 2016
 
9  PROTOCOL AMENDMENT 
 
Protocol Number:  ISIS 396443-CS3A 
Protocol Title: A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics 
of Multiple Doses of Nusinersen (IS IS 396443) Delivered Intrathecally to 
Patients with Infantile-Onse t Spinal Muscular Atrophy  
Amendment: 6 
Amendment Date:  25 January 2016 
 
The following modifications to Protocol  ISIS 396443-CS3A, have been made. 
Minor changes (not included in the list of changes below) have been made throughout the protocol to correct errors and/or to improve the overall clarity of  the original protocol but these 
changes do not impact subject safety, exposure, or the overall study design. 
If there are more than 1 or 2 changes, insert the following table. 
The following table provides a summary list of major changes to the protocol: 
Protocol Section Description of Change Rationale 
Study Title  Added “Efficacy” and “Nusinersen” Study title was updated to appropriately 
reflect the study objectives.  Nusinersen 
is an approved USAN name for ISIS 396443. 
Protocol Synopsis: Objectives , 
Section 1: Objectives  Amended Study Objectives to reflect efficacy assessment as the 
primary study objective and safety 
and tolerability as the secondary 
study objectives. Study is of sufficient duration now to 
assess the efficacy of nusinersen in this 
patient population. 
Protocol Synopsis: Criteria for Evaluation  
Section 10.1: Study Endpoints  Efficacy and Safety endpoints are listed according to the amended 
study objectives Efficacy endpoints related to motor 
function and event-free survival 
represent the most meaningful endpoints 
in this patient population. 
Section 10.5 : Planned Methods 
of Analysis  Inserted the methods for analysis of efficacy endpoints of the study Description of the methodology for analysis of the efficacy endpoints related 
to motor function and event-free survival 
was included to clarify how these data 
will be analyzed and presented. 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
10  PROTOCOL SYNOPSIS  
Protocol Title  A Study to Assess the Efficacy, Safety, Tolerability , and Pharmacokinetics  of Multiple 
Doses of Nusinersen ( ISIS 396443) Delivered Intrathecally to Patients with Infantile-
Onset Spinal Muscular Atrophy 
Study Phase  2 
Indication  Spinal Muscular Atrophy (SMA) 
Objectives  Primary  Objective: 
To examine the clinical efficacy  of multiple doses of ISIS  396443 administered 
intrathecally to patients with Infantile-Onset SMA . 
Secondary Objectives: 
To examine the safety and tolerability of multiple doses of ISIS 396443 administered 
intrathecally to patients with Infantile-Onset SMA. 
To examine the CSF and plasma pharmacokinetics of multiple doses of ISIS 396443 
administered intrathecally to patients with Infantile-Onset SMA.  
Number of Subjects  Approximately 8-20 subjects may  be enrolled into this multiple-dose study of 
ISIS 396443.  The number of subjects may be higher if some subjects must be replaced 
and/or if the sizes of cohorts are expanded in order to obtain further experience with 
one or both dose levels.  
Study Design and 
Methodology  This study will test the clinical efficacy, safety, tolerability, and pharmacokinetics of 
multiple doses of ISIS 396443  administered as intrathecal  (IT) injections by lumbar 
puncture (LP).  All subjects  will receive ISIS  396443.  Two ‘loading’ dose levels (scaled 
by infant age to be equivalent to 2 year old doses of 6 mg or 12 mg, based on CSF 
volume) will be evaluated sequentially.  The initial dose level of 6 mg will be studied in a 
cohort of 4 subject s.  The 12 mg dose level will be studied in 4 to approximately  
16 subjects.  Following this, all subjects will receive ‘maintenance’  doses of 12 mg 
equivalent ISIS 396443 on Days  253, 379, 505, 631, 757, 883, 1009, 1135, and 1261. 
Cohort 1 (n = 4):  ‘Loading’ dosing of 6 mg equivalent ISIS 396443  on Days 1, 15, 85, 
IT injection; followed by ‘maintenance’  doses of 12 mg equivalent ISIS 3 96443 on 
Days  253, 379, 505, 631, 757,  883, 1009, 1135, and 1261  IT injection . 
Cohort 2 (n = 4-16) :  ‘Loading’ dosing of 12 mg equivalent ISIS 396443 on Days  1, 15, 
85, IT injection; followed by ‘maintenance’  doses of 12 mg equivalent ISIS 396443 on 
Days  253, 379, 505, 631, 757,  883, 1009, 1135, and 1261 IT injection . 
After Informed consent is obtained, subjects will undergo a Screeni ng evaluation no 
greater than 21 days prior to first dose administration at which their eligibility for the 
study will be examined.  Subjects who meet the eligibility criteria will be admitted to the 
study center on Study Day  1, undergo pre -dose evaluations, and then receive an LP 
inject ion of Study Drug  (ISIS  396443).  Subjects will ret urn to the study center on 
Days  15, 85, 253 , 379, 505, 631, 757, 883, 1009, 1135, and 1261 for follow -up 
evaluations of clinical efficacy and safety and subsequent injections.  Following the LP 
injection on Day 1, subjects will remain at the study center for at least 24 hours post -
injection for safety monitoring.  Following LP injections on Days  15, 85, 253, 379, 505, 
631, 757, 883, 1009, 1135, and 1261, subjects will remain at the study center for at 
least 6 hours post -injection for safety monitoring.  Safety monit oring visits will occur on 
Days  16, 29, 86, 92, 169, 254, 337, 442, 568, 694, 820, 946, 1072, 1198, and 1352 
(through 13  weeks after the last dose of ISIS 396443).  In addition, the study center will 
monitor the subject’s condition through telephone contact on  Study  Days 8, 43, 57, 71, 
106, 127, 134, 148, 189, 197, 218, 239, 274, 295, 316, 358, 380, 400, 421, 463, 484, 
506, 526, 547, 589, 610, 632, 652, 673 , 715, 736, 758, 778, 799, 841, 862, 884, 904, 
925, 967, 988, 1010, 1030, 1051, 1093, 1114, 1136, 1156, 1177, 1219, 1240, 1262, 
1282, 1303, and 1324 (i.e., approximately every 3  weeks).  
A CSF sample will be taken pre-dose on each injection day for safety laboratory evaluation and PK analyses.  
If a subject terminates early from the study, they will be encouraged to complete 
assessments per the Day 1352  visit. 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
11  Protocol Synopsis Continued  
Study Population and 
Main Cri teria for  
Inclusion/ Exclusion  Inclusion Criteria : 
Subjects must meet all of the following criteria at screening to be eligible:  
1. Signed informed consent of parent(s) or guardian(s) 
2. Genetic documentation of 5q SMA homozygous gene deletion or mutation  
3. Onset of clinical signs and symptoms consistent with SMA at ≥ 21 days and 
≤ 6 months (180 days)  of age  
4. Males and females between ≥ 21 days and ≤ 7 months (210 days) of age at 
Screening  
5. At study entry, receiving adequate nutrition and hydration (with or without 
gastrostomy) , in the opinion of the Site Investigator  
6. Body weight >  5th percentile for age using CDC guidelines  
7. Medical care meets and is expected to continue to meet guidelines set out in the 
Consensus Statement for Standard of Care in SMA ( Wang et al.  2007), in the 
opinion of the Site Investigator  
8. Gestational age of 35 to 42 weeks and gestation body weight ≥ 2 kg 
9. Reside within approximately 9 hours ground-travel distance from a participating 
study center  for the duration of the study. Residence >  2 hours ground-travel 
distance from a study center must obtain clearance from the Site Investigator  and 
the study Medical Monitor  
10. Able to complete all study procedures, measurements and visits and parent or 
guardian/subject  has adequately supportive psychosocial circumstances, in the 
opinion of the Site Investigator  
Exclusion Criteria: 
Subjects meeting any of the following criteria are not eligible for the study:  
1. Hypoxemia (O2 saturation awake <  96% or O2 saturation asleep <  96%, without 
ventilation support ) 
2. Presence of an untreated or inadequately treated active infection requiring 
systemic antiviral or antimicrobial therapy at any time during the screening period  
3. History of brain or spinal cord disease that would interfere with the LP procedures , 
CSF circulation , or safety assessments  
4. Presence of an implanted shunt for the drainage of CSF or an implanted CNS 
catheter  
5. History of bacterial meningitis  
6. Clinically significant abnormalities in hematology or clinical chemistry parameters, 
as assessed by the Site Investigator, at Screening that would render the subject  
unsuitable for inclusion  
7. Treatment with another investigational drug ( e.g., albuterol, riluzole, carnitine, 
creatine, sodium phenylbutyrate, salbutamol, valproate, hydroxyurea etc .), 
biological agent, or device within 90 days prior to enrollment or anytime during the 
study.  Any history of gene therapy or cell transplantation  
8. The subject’s parent(s) or legal guardian(s) is unable to understand the nature, 
scope, and possible consequences of the study, or does not agree to comply with 
the protocol defined schedule of assessments  
9. Ongoing medical condition that according to the Site Investigator would interfere 
with the conduct and assessments of the study.  Examples are medical disability  
other than SMA  that would interfere with the assessment of safety or would 
compromise the ability of the subject  to undergo study procedures  
ISIS 396443-CS3A CONFIDENTIAL Amendment 6
Protocol 25 January 2016
 
12  Protocol Synopsis Continued 
Study Drug and 
Administration ISIS 396443 (20 mg/mL, 2.5 mL, diluted to specified concentration with artificial CSF diluent OR 2.4 mg/mL as ‘Ready-to-Use Vial’; see Section 7.1.2. for more details) will 
be administered as an IT LP injection.  The volume of the inject ion and thus the dose 
will be adjusted for the subject’s age, based on scaling to CSF volume.  Thus, younger 
subjects will be given a lower dose of drug, ac hieved by injecting a smaller volume that 
is proportional to estimated CSF volume for age, such that dose volume will be equivalent to 5 mL for age 2 to adult. Dosing instructions and details regarding 
administration will be provided  in the Study Drug Manual. 
Criteria for Evaluation Efficacy Evaluations: 
 Achievement of motor milestones as evaluated by the Hammersmith Infant 
Neurological Examination (Module 2) 
 Event-free survival determined by the pr oportion of subjects who are alive and do 
not require permanent ventilatory support (defined as ≥ 16 hours ventilation/day 
continuously for at least 14 days in the absence of an acute reversible illness) 
 Improvement in muscle strength as m easured by the Children's Hospital of 
Philadelphia Infant Test for Neuromuscular Disease (CHOP INTEND) 
 Improvement in neuromuscular electrophysiology measured by the Compound 
Muscle Action Potential (CMAP) of the ulnar and peroneal nerves 
 Measures of respiratory status (number of respiratory events, respiratory-related 
hospitalizations, ventilator use) 
 Growth parameters (weight for age/length, head circumference, chest 
circumference, head to chest circumference ratio, arm circumference) 
Safety/Tolerability Endpoints: 
 Adverse events 
 Vital signs (HR, BP, respiratory rate, pulse oximetry awake) 
 Neurological examinations 
 Physical examinations and weight 
 Clinical laboratory tests  
 CSF laboratory tests  ECGs 
 Use of concomitant medications 
Pharmacokinetic Measures: 
 Plasma levels of ISIS 396443 
 CSF levels of ISIS 396443 
Additional Measures: 
 SMN2 copy number (if no Athena result existing)  SMN2 gene sequencing (if no Athena result existing) 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
13  Protocol Synopsis Continued  
Safety Monitoring and 
Dose Escalation  Safety data will be reviewed on an ongoing basis by the Medical Monitor and by the 
DSMB.  
At the onset of the study, a Dose-Limiting-Toxicity (DLT) is defined as an adverse event 
that in the judgment of a Site Investigator is of sufficient significance to be dose limiting,  
is possibly or definitely related to Study Drug  (i.e., the adverse event is substantially 
less likely to occur in patients not treated with Study Drug), and that is not a known:  
1) sign or symptom of SMA disease, or 2) effect of the LP injection procedure, or 
3) effect of anesthesia/sedation in SMA patients , if utilized.  
The progression of the study from the initial dose level (Cohort 1) to Cohort 2 will be 
determined by the Sponsor and the DSMB and generally be based on the number of DLTs observed in patients treated with ISIS  396443.  In general, the occurrence of 
DLTs in 2 patients in Cohort 1 may result in the dose tested being considered as dose 
limiting.  The occurrence of 1 DLT in 4 subjects in Cohort 1 may result in the cohort 
being expanded to 6 subjects (2 additional subjects) to further assess the safety within that dose level.  After the last patient within Cohort 1 completes the Day 29 visit, safety 
results for the cohort will be reviewed by the Medical Monitor and the DSMB and a 
recommendation regarding further enrollment and escalation to Cohort 2 will be made.  
The Sponsor and DSMB will determine if enrollment of additional patients is required to 
confirm there is an acceptable toxicity profile pri or to its designation as MTD.  
Statistical 
Considerations  The sample size selection is based on prior experience to ensure that the safety, 
tolerability, and pharmacokinetics will be adequately assessed while minimizing 
unnecessary patient exposure rather than statistical considerations for the efficacy 
endpoints . 
Interim efficacy and safety analyses will be performed to provide content for regulatory 
submissions and to support ISIS 396443 drug development planning and business 
activities.  Details o f the analyses are contained in the Statistical Analysis Plan.  
Sponsor  Ionis Pharmaceuticals, Inc. 
  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
14  STUDY GLOSSARY 
Abbreviation/Acronym Definition  
AE Adverse event/e xperience 
ALT  Alanine aminotransferase  
aPTT  Activated partial thromboplastin time  
ASO Antisense oligonucleotide 
AST  Aspartate aminotransferase 
BUN  Blood urea nitrogen 
CMAP  Compound muscle action pot ential  
Cmax Maximum concentration 
CNS  Central nervous system 
CPK  Creatinine phosphokinase 
CRF  Case report form  
CSF Cerebrospinal fluid 
CT Computerized tomography 
DLT  Dose limiting toxicity  
DSMB  Data and Safety Monitoring Board 
eCRF  Electronic  case report f orm 
ECG  Electrocardiogram  
FL Full-length  
GCP  Good Clinical Practice  
HFMSE  Hammersmith Functional Motor Scale Expanded 
hnRNP Heterogeneou s nuclear ribonucleoproteins 
ICH International Conference on Harmonisation  
INR International normalized r atio 
IRB Institutional Review Board  
IT Intrathecal  
LP Lumbar puncture 
MAD Multiple ascending-dose 
MedDRA  Medical Dictionary for Regulatory A ctivities  
miRNA  Micro ribonucleic acid (RNA)  
MOE  2′-O-(2-methoxyethyl)  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
15  MRI  Magnetic resonance imag ing 
mRNA Messenger ribonucleic acid 
MTD  Maxim um tolerated do se 
NCS  Not clinically si gnificant  
NOAEL  No observed adverse effect level  
PK Pharmacokinetic(s)  
PT Prothrombin Time 
SAE  Serious adverse event  
SMA  Spinal muscular atro phy 
SMN  Survival motor neuron 
snRNA Small nuclear ribonucleic acid  
SUSARs  Suspected  unexpected serious adverse r eactions  
t½ Terminal  elimination half -life 
TIMPSI  Test for Infant Motor Performance Screening Items 
Tmax Time to maximal c oncentration 
WMA  World Medical Association  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
16  1. OBJECTIVES  
The objectives of this study are to evaulate the clinical efficacy, safety, tolerability, and 
pharmacokinetics  (PK) of multiple dose s of ISIS 396443 administered intrathecally to  patients 
with infantile -onset Spinal Muscular Atrophy (SMA). 
1.1 Primary Objective  
To examine the clinical efficacy of multiple doses of ISIS 396443 admi nistered intrathecally to 
patients with Infantile -Onset SMA . 
1.2 Secondary Objectives 
To examine the safety and tolerability of multiple doses of ISIS 396443 administered 
intrathecally to patients with infantile -onset SMA.  
To examine the cerebral spinal fluid ( CSF) and plasma PK of multiple doses of ISIS 396443 
administered intrathecally to patients with infantile -onset SMA.  
2. BACKGROUND AND RATIO NALE  
2.1 Spinal Muscular Atrophy  
SMA is an autosomal recessive neuromuscular disease characterized by degener ation of the 
motor neurons in the anterior horn of the spinal cord, resulting in atrophy of the voluntary 
muscles of the limbs and trunk.  With an incidence of 1:6000 to 1:10,000 live births, it is the most common genetic cause of infant mortality, and a major cause of childhood morbidity due to weakness, in the U.S.  The natural history of SMA includes four major phenotypes that are recognized dependent on age of onset and achieved motor abiliti es.  The most severe form, 
Type  I SMA, has a disease onset within the first few months of life; these children are never able 
to sit or walk and usually die from respiratory failure by the age of 2  years.  Type II SMA 
patients are able to sit but never walk unaided, with symptoms presenting between 6-18 months of age .  Type III SMA patients are able to sit and walk but individuals with this form may 
become severely and incr easingly disabled.  Type IV or adult-onset SMA patients have an age of 
onset over 18 years of age and have normal life expectancies.  
In 95% of SMA patients, a deletion in the SMN1 gene on Chromosome 5q11-q13 is found; with 
the remaining 5% attributable to small mutations in the same gene ( Lefebvre et al. 1995; 
Helmken et al. 2003).  SMN1  lies in the telomeric portion of an inverted duplication of a r egion 
of Chromosome 5.  The centromeric half of the duplication contains a homologous gene, named SMN2  that differs from SMN1  by 11 nucleotides.  The open reading frames for both genes 
encode for proteins with identical amino acid sequences.  Survival motor neuron ( SMN ) gene 
transcripts, similar to most mammalian transcripts, undergo alternative splicing in which certain exons are either included or excluded from the mature protein coding transcripts (Keren  et al. 2010).  In particular, Exon  7 of the SMN1  gene is alternatively spliced with 90 to 
95% of the mature m essenger ribonucleic a cid (mRNA) transcripts derived from the SMN1  gene 
containing Exon  7, and 5 to 10% of transcripts missing Exon  7.  The transcripts missing Exon  7 
(often referred to as Δ7) pr oduce a truncated protein which is defective and unstable 
(Cho et  al. 2010).  One (1) of the 11 nucleotide differences between SMN1  and SMN2 , a C to T 
substitution occurs in Exon 7 of the SMN2  gene resulting in an alternative splicing pattern that 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
17  favors s kipping of Exon  7.  The result is that as much as 90% of the transcripts produced from 
SMN2  are missing Exon  7.  The remainder, SMN2 transcripts containing Exon  7, produces a 
full-length (FL) protein product identical to the SMN1 protein, since the C to T substitution is 
silent. Humans have a variable copy number of the SMN2  gene (0 -8 copies).  The number of 
SMN2  copies and the resulting amount of FL-SMN protein expressed in SMA patients (10-40% 
of normal SMN protein levels) correlates with SMA disease severity and thus SMN2  is a key 
modifier of disease phenotype ( Coovert et al. 1997; Lefebvre et  al. 1997; Feldkotter et al. 2002; 
Prior et al. 2004).  
2.2 Therapeutic Rationale 
Since the number of SMN2 gene copies and resulting amount of SMN protein is correlated with 
disease onset and severity, a therapeutic approach predicted to benefit SMA patients is to increase the levels of full length SMN2 pre- mRNA by restoring the splicing pattern that gives 
rise to full length SMN2 mRNA.  Increasing inclusion of Exon  7 in the SMN2 transcript will 
increase FL -SMN protein levels and SMN protein activity.  A therapeutic strategy for promoting 
Exon  7 inclusion is through the use of antisense oligonucleotides (ASOs) (see Figure 1 ). 
 
Figure 1 ASO Therapeutic Approach for Treatment of SMA  
 

ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
18  The known potential risks associated with ISIS 396443 are elaborated on in the Guidance to 
Investigator section of the Investigator’s Brochure.  Additional s tudy associated risks relate to 
the lumbar puncture (LP) procedure are also elaborated on in the Guidance to Investigator 
section of the Investigator’s Brochure. 
2.3 ISIS  396443 
2.3.1 Mechanism of Action  
ISIS 396443 is a fully modified , 2′-O-2-methoxyethyl (MOE), ASO drug designed to bind to a 
specific sequence in the intron downstream of Exon  7 of the SMN2 transcript.  The region of the 
pre-mRNA targeted by ISIS 396443 is normally occupied by heterogeneous nuclear 
ribonucleoproteins (hnRNP) A1/2  proteins, masking the U1 small nuclear ribonucleic acid 
(snRNA) binding site at the 5′ -exon -intron junction of Exon  7, and is referred to as ISS -N1.  
U1 snRNA base pairs to the sequences that define the 5 ′-splice site, which is thought to be one of 
the first steps that initiates splicing of an intron.  ISIS 396443 displaces the h nRNP A1/2 proteins 
from the pre -mRNA binding site, allowing U1  snRNA to bind to the exon-intron junction and 
promote assembly of the spliceosomal complex, thus promoting inclusion of Exon  7 into the 
mRNA which results in production of FL -SMN protein. 
2.3.2 Chemistry  
Chemically, ISIS 396443 is a synthetic oligomer of 18 nucleotides (i.e., an 18- mer) that are 
connected sequentially by phosphorothioate linkages.  Each of the 17 internucleotide linkages is 
a 3′-O to 5′ -O phosphorothioate diester.  The 18 sugar residues are uniformly modified with 
2′-O-(2-methoxyethyl) (MOE).  These MOE -modified nucleotides confer (1) increased affinity 
to the target mRNA ( McKay et al. 1999), (2) increased resistance to exonucleases and 
endonucleases (thereby increasing stability in tissue) ( Geary et al. 2003 ), and (3) ameliorat ion of 
some of the high dose toxicities associated with ASO containing only the phosphorothioate 
linkages ( Henry et al. 2000 ). 
The sequence of ISIS 396443 is written as follows: 
5′ -MeUMeCAMeCMeUMeUMeUMeCAMeUAAMeUGMeCMeUGG- 3′ 
Where A and G are 2 ′-O-(2-methoxyet hyl)nucleosides, MeC is 5 -methyl -2′-O-(2-
methoxyethyl)cytidine and MeU designates 5 -methyl -2′-O-(2-methoxyethyl)uridine.  
2.3.3 Preclinical Experience  
Detailed information concerning the preclinical studies conducted with ISIS 396443 can be 
found in the Investigator ’s Brochure.  A summary is included below. 
ISIS 396443 was identified after an extensive screen of greater than 500 2′ -MOE 
oligonucleotides in in vitro  splicing assays, reporter gene assays and in SMA patient fibroblasts 
(Hua et al. 2007; Hua et al. 2008).  Data have shown that ISIS 396443 promotes a 
concentration -dependent increase in full -length transcripts (including Exon 7) in patient 
fibroblast cells, achieving greater than 90% full length SMN2 transcripts and forms nuc lear 
structures, called gems, known to contain SMN protein.  In a mild mouse model of SMA, 
ISIS 396443 promoted inclusion of Exon 7 in the SMN2 transgene in a variety of peripheral 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
19  tissues when dosed systemically ( Hua et al. 2008 ) and in central nervous sy stem ( CNS ) tissue, 
including spinal cord, when injected  into the lateral ventricle.  ISIS 396443 produced greater 
than 90% Exon  7 inclusion in the transgenic mice and increased SMN protein production in 
motor neurons, resulting in the appearance of gems in motor neurons.  These studies were 
extended to a more severe mouse model of SMA (SMA Δ7) ( Le et al. 2005 ), where the CNS 
delivery of drug produced a dose-dependent effect on SMN2 Exon  7 inclusion, SMN protein 
production, and survival.  These mice treated with ISIS 396443 demonstrated improved weight 
gain, improvements in muscle morphology, muscle strength, and motor coordination and 
improved morphology of the motor neuron junctions ( Passini et al. 2011).  Further, ISIS 396443 
was shown to distribute widely in the CNS following intrathecal (IT)  administration in monkey 
(Passini et al. 2011).  
The pharmacokinetics and toxicity of ISIS 396443 w ere assessed following:  1) single intrathecal 
(IT) lumbar bolus injections (1 to 7 mg) in adult monkeys 2) following 14 weeks (with a 4 -week 
interim sacrifice) of repeated IT lumbar bolus injections (0. 3 to 3 mg/ wk or every other week) in 
juvenile monkeys and 3) following 1- year of repeated IT lumbar bolus injections in juvenile 
monkeys.  Detailed results from these prec linical studies conducted with ISIS 396443 can be 
found in the Investigator’s Brochure. 
2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with ISIS 396443 can be found in 
the Investigator’s Brochure .  A summary is inc luded below. 
ISIS 396443 has been evaluated  in a completed open -label, single ascending -dose (SAD) Phase 1 
study designed to assess the safety, tolerability and pharmacokinetics of ISIS 396443 in patients 
with SMA ( ISIS 396443-CS1).  A single-dose of ISIS 396443 wa s administered by IT injection 
to SMA patients aged 2 to 14 years of age.  Four (4) dose levels (1, 3, 6, and 9 mg) were 
evaluated sequentially.  Each dose level was  studied in a cohort of 6 or 10 patients, where all 
patients received drug.   In this study  all subjects complet ed dosing and the follow-up visits per 
protocol.  Overall, ISIS 396443 was  well -tolerated and no safety concerns were identified up to 
the 9.0 mg dose level, given as a single IT injection.   No serious adverse events (SAEs) or dose-
limiting toxicities (DLTs) were reported in ISIS 396443-CS1.  Adverse events (AEs) reported 
were mild or moderate in severity and there was no  relat ionship with ISIS 396443 dose level. In 
addition, no ISIS 396443 related adverse changes in neurologi cal exams were reported, despite 
intensive monitoring during the immediate post-dosing period.  CSF and plasma drug 
concentrations observed were generally consistent with predictions made from nonclinical 
monkey studies. 
ISIS 396443 is also being evaluated in seven  ongoing studies: ISIS 396443-CS2, 
ISIS 396443- CS10, ISIS  396443-CS12, ISIS 396443-CS3B (ENDEAR), ISIS 396443-CS4 
(CHERISH), 232SM201 (NURTURE) and 232SM202 (EMBRACE). 
ISIS 396443-CS10 is an open- label, single do se, re-dosing study for SMA patients who 
previously participated in Cohorts 2, 3 and 4 in ISIS 396443-CS1. ISIS 396443-CS2 is an open- label, multiple ascending -dose (MAD) Phase 1/2a study designed to 
assess the safety, tolerability and pharmacokinetics of ISIS 396443 in patients with SMA.  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
20  Multiple doses of ISIS 396443, ranging from 3 mg to 12 mg, are being administered by 
intrathecal injection to SMA patie nts aged 2 to 15 years of age. 
ISIS 396443-CS12 is an open- label , multiple -dose study to assess the sa fety and tolerability of a 
12 mg dose level of ISIS  396443 administered intrathecally in patients with spinal muscular 
atrophy who previously participated in ISIS  396443-CS2 or ISIS 396443-CS10. 
ISIS 396443-CS3B (ENDEAR) is a randomized, double-blind, sham-procedure controlled study 
designed to assess clinical efficacy and safety of ISIS  396443 in patients with infantile-onset 
SMA.  A 12 mg dose equivalent scaled by CSF volume is being evaluated in symptomatic SMA infants ≤ 7 months  at the time of consent  of age utilizing a loading regimen of 4 intrathecal doses 
on Days 1, 15, 29 and 64, followed by a q4 months maintenance period. 
ISIS 396443- CS4 (CHERISH)  is a randomized, double-blind, sham-procedure controlled study 
designed to assess clinical efficacy and  safety of ISIS  396443 in patients with later-onset SMA 
aged 2 -12 years .  A 12 mg dose is being evaluated utilizing a loading regimen of 3 intrathecal 
doses on Days 1, 29 and 85, followed by a q6 months maintenance period. 
232SM201 (NURTURE) is an open- label study to assess the efficacy, safety, tolerability and 
pharmacokinetics of multiple doses of ISIS 396443 delivered intrathecally to subjects with 
genetically diagnosed and pre- symptomatic SMA.  
232SM202 (EMBRACE) is a randomized, double-blind, sham-procedure controlled study to 
assess safety and tolerability and to explore efficacy of ISIS 396443 administered intrathecally in subjects with SMA who are not eligible to participate in the clinical studies ISIS 396443- CS3B 
or ISIS 396443- CS4. 
2.4 Rationale for Dose and Schedule of Administration 
The proposed study will test the clinical efficacy, safety, tolerabi lity, and PK  of multiple doses of 
ISIS 396443 administered as IT injection s.  Two  (2) ‘loading’ dose levels (scaled by infant age 
to be equivalent to 2 year old doses of 6 mg  or 12 mg, based on CSF volume ) will be evaluated 
sequentially , given during a‘loading’ dosing period on Study Days 1, 15, and 85.  Following that, 
all subjects will be given ‘maintenance’ doses of 12 mg equivalent ISIS 396443 on 
Study Days  253, 379, 505, 631, 757, 883, 1009, 1135, and 1261. 
ISIS 396443 dose levels and dose interval for ISIS 396443- CS3A were selected based on 
preclinical toxicology and pharmacokinetic observations from monkey studies utilizing single-
dose and repeat dosing (for 14 weeks) IT administration, consideration of the target tissue concentration anticipated for drug pharmacology, and safety data in the completed and ongoing clinical studies of ISIS 396443 to date.  Based upon pharmacology and pharmacokinetic results in SMA transgenic mice, we estimate that the target t issue concentration to produce 50 to 90% 
SMN2 Exon 7 inclusion is between 1 and 10 µg/g spinal cord tissue.  Nonclinical studies in juvenile monkeys receiving IT doses of ISIS 396443 showed a resulting gradient of distribution of ISIS 396443 along the spinal cord, with mean lumbar spinal cord concentrations ranging from 1.6-2.3 fold and 2.0-3.5 fold higher than thoracic and cervical spinal cord levels, respectively.  The lowest dose selected for this multiple -dose clinical study (6  mg ISIS  396443) is predicted to 
achieve spinal cord tissue concentrations at the low end of this range (approximately 6 µg/g lumbar and 2 μ g/g cervical concentrations), while the highest dose (12 mg ISIS 396443) is 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
21  predicted to achieve levels at the high end of this range (approximately 10 µg/g lumbar and 
3 μg/g cervical spinal cord tissue concentrations), following the first dose. 
The loading dose interval was selected based on the nonclinical pharmacokinetic and 
pharmacology data as the dose interval to achieve and maintain ISIS  396443 spinal cord tissue 
levels that are predicted to be within the upper end of the pharmacologically active range by Day 85 (predicted to be approximately 30 µg/g lumbar and 10 µg/g cervical tissue 
concentration), while at the same time considering subj ect safety and convenience for repeated 
LP intrathecal injections.  The maintenance dose interval (once every 4  months) was selected 
based on the estimated spinal tissue and CSF drug half- life (4 -6 months) and was selected to 
maintain spinal cord tissue le vels of ISIS 396443 at a steady- state level within the estimated 
pharmacologically active range.  
Additional details on dose scaling and expected CSF and tissue concentrations are summarized 
in the Investigator’s Brochure.  
3. EXPERIMENTAL PLAN 
3.1 Study Design  
This study will test the clinical efficacy, safety, tolerability, and PK  of multiple doses of 
ISIS 396443 administered as IT injections by LP.  Two  (2) ‘loading’ dose levels (scaled by 
infant age to be equivalent to 2 year old doses of 6 mg  or 12 mg , based on CSF volume ) will be 
evaluated sequentially.  The initial dose level of 6 mg will be studied in a cohort of 4 subjects.  
The 12 mg dose level will be studied in 4 to approximately 16 subjects.  Following this, all 
subjects will receive  ‘maintenan ce’ doses of 12 mg equivalent ISIS 396443 on Days  253, 379, 
505, 631, 757, 883, 1009, 1135, and 1261.  
Cohort 1 (n  = 4) :  ‘Loading’ dosing of 6 mg equivalent ISIS 396443 on Days  1, 15, 85, 
IT injection ; ‘maintenance’  doses of 12 mg equivalent on Days  253, 379, 505, 631, 757, 883, 
1009, 1135, and 1261, IT injection . 
Cohort 2 (n  = 4-16) :  ‘Loading’ dosing of 12 mg equivalent ISIS 396443 on Days  1, 15, 85, 
IT injection, ‘maintenance’  doses of 12 mg equivalent on Days  253, 379, 505, 631, 757, 883, 
1009, 1135, 1261, IT injection . 
3.2 Number of Study Centers  
This study will be conducted at multiple centers  in the United States  and Canada. 
3.3 Number of Subjects  
Approximately 8-20 subjects will be enrolled into this multiple -dose study of ISIS 396443.  The 
number of subjects may be higher if some subjects must be replaced and/or if the sizes of some 
cohorts are expanded in order to obtain further experience with some dose levels. 
3.4 Overall Study Duration and Follow- up 
The Study will consist of screening, t reatment  period including ‘loading’ dosing and 
‘maintenance’  dosing, and post- treatment follow -up period.  The total duration of participation in 
the study is approximately 3.7 years.  Please refer to the Schedule of Procedures in Appendix A . 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
22  3.4.1 Screening  
After informed consent/assent is obtained, subjects will undergo a Screening evaluation no 
greater than 21  days prior to first dose administration at which their eligibility for the study will 
be examined.  
3.4.2 Treatment  
Subjects who meet the el igibility criteria will be admitted to the study center on Study Day 1, 
undergo pre-dose evaluations, and then receive an LP injection of Study Drug  (ISIS 396443).  
The subject will remain at the study center for at least 24 hours post- injection for safety  
monitoring and laboratory specimen collection.  Subjects will retur n to the tudy center on 
Days  15, 85, 253, 379, 505, 631, 757, 883, 1009, 1135, and 1261 for follow -up evaluations and 
subsequent injections.  Following LP injections on S tudy Days 15, 85, 253, 379, 505, 631, 757, 
883, 1009, 1135, and 1261 subjects will not stay overnight in the hospital but will be monitored 
for at least 6 hours post- injection before leaving the study facility.   A CSF sample will be taken 
pre-dose on each injection day for safety and Pharmacokinetic ( PK) analyses.   During the 
treatment period, t he study center will monitor the subject’s condition through saf ety monitoring 
visits on Study Days 16, 29, 86, 92, 169, 254, 337, 442, 568, 694, 820, 946, 1072, and 1198, and 
by telephone contact on Study Days 8, 43, 57, 71, 106, 127, 134, 148, 189, 197, 218, 239, 274, 
295, 316, 358, 380, 400, 421, 463, 484, 506, 526, 547, 589, 610, 632, 652, 673, 715, 736, 758, 778, 799, 841, 862, 884, 904, 925, 967, 988, 1010, 1030, 1051, 1093, 1114, 1136, 1156, 1177, 
1219, 1240, 1262, 1282, 1303, and 1324 (i.e. , approximately every 3 weeks).  
3.4.3 Post-Treatment  Follow -up 
During the post- treatment follow -up period, t he study center will monitor the subject’s condition 
through telephone contact on Study Days  1282, 1303, and 1324 (i.e., every 3 weeks through 
13 weeks after the last dose of ISIS 396443).  A s afety monitoring visit will occur on Day  1352 
(through 13 weeks after the last dose of ISIS 396443).  
If a subject terminates  early from the study, they will be encouraged to complete all assessments 
per the Day  1352 visit.  
3.5 End of Study  
The end of study is last subject, last visit (either in -person visit or telephone contact). 
3.6 Safety Monitoring and Dose Escalation 
Safety data will be reviewed on an ongoing basis by the Sponsor and the Ionis Medical Monitor. 
Safety data will also be reviewed on an ongoing basis by an  independent Data and Safety 
Monitoring Board ( DSMB ). 
The progression of the study from the initial dose level (Cohort 1) to Cohort 2 will be determined 
by the Sponsor and the DSMB and generally be based on the number of DLTs observed in patients treated with ISIS 396443.  In general, the occurrence of DLTs in 2 patient s in Cohort 1 
may result in the dose tested being considered as dose limiting.  The occurrence of 1 DLT in 
4 subjects in Cohort 1 may result in the cohort being expanded to 6 subjects (2 additional 
subjects) to further assess the safety within that dose level.  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
23  After the last patient within Cohort 1 completes the Day 29 visit, safety results for the cohort will 
be reviewed by the Sponsor and the DSMB and a recommendation regarding further enrollment 
and escalation to Cohort 2 will be made.   The Sponsor and DSMB w ill determine if enrollment 
of additional patients is required to confirm there is an acceptable toxicity profile prior to its 
designation as MTD. 
3.7 Dose Limiting Toxicity  
At the onset of the study, a DLT is defined as an adverse event that in the judgment of a 
Site Investigator is of sufficient significance to be dose limiting, is possibly or definitely related 
to Study Drug  (i.e., the AE is substantially less likely to occur in subjects  not treated with 
Study Drug), and that is not a known:  1) sign or symptom of SMA disease, or 2) effect of the LP 
injection procedure. 
If a suspected DLT occurs during injection of Study Drug , treatment of the subject  with Study 
Drug  should be stopped (i.e. , the injection should be immediately discontinued).  The Site 
Investigator should contact the Ionis Medical Monitor as soon as possible following any dosing 
discontinuations to discuss the case.  The DSMB will also be informed and will determine if any 
relevant findings have been observed with other subject s in the study. 
Subjects that experience a DLT will discontinue study treatment but will be monitored by follow-up safety visits. 
4. SUBJECT ENROLLMENT 
4.1 Screening  
Before subjects  may be enrolled into the study, the Sponsor requires a copy of the Study Center ’s 
written  Institutional Review Board (IRB) or Research Ethics Board (REB) approval of the 
protocol, informed consent form, informed assent form (if applicable) and all other subject 
information and/or recruitment material. 
Before a subject’s  participation in the trial, the Investigator is responsible for obtaining written 
informed consent from the parent (s) or legal guardian (s).  At the time of consent, the subject  will 
be considered enrolled into the s tudy and will be assigned  a unique screening number before any 
study procedures, including screening procedures, are performed.  At the time of registration , 
subjects will be assigned a unique subject identification number.  This number will be used to 
identify the subject throughout the trial and must be used on all stud y documentation related to 
that subject.  The screening number and subject identification number must remain constant throughout the entire trial.  In the event the subject is re-consented and re-screened the subject 
must be given a new screening number.  Screening numbers and subject identification numbers, 
once assigned, will not be re-used. 
4.2 Registration 
Subjects will be registered after all screening assessments have been completed and after the 
Investigator and the Ionis M edical Monitor have verified that they are eligible per criteria in 
Sections 5.1 and 5.2. 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
24  No subject may begin treatment prior to registration  and assignment of a unique subject 
identification number. 
4.3 Replacement of Subjects  
If a subject  withdraws from the trial prior to the administration of Study Drug, the subject  will be 
replaced.  If a subject  withdraws for reasons other than safety after receiving any amount of 
Study Drug  and prior to the Day 85 visit, the Site Investigator  and the Ionis Medical Monitor will 
discuss the reason(s) for the discontinuation and the appropriateness of enrolling a replacement 
subject .  If a subject withdraws for safety reasons that are potentially drug related after receiving 
any amount of Study Drug , the DSMB will review the case and provide recommendations 
regarding replacement of the subject . 
5. SUBJECT ELIGIBILITY  
5.1 Inclusion Criteria  
To be eligible to participate in this study candidates must meet the following eligibility criteria at 
screening.  
1. Signed informed consent of parent(s) or guardian(s) 
2. Genetic documentation of 5q SMA homozygous gene deletion or mutation 
3. Onset of clinical signs and symptoms consistent with SMA at ≥  21 days and ≤  6 months 
(180 days) of age 
4. Males and females betwe en ≥ 21 days and ≤  7 months (210 days) of age at S creening  
5. At study entry, receiving adequate nutrition and hydration (with or without gastrostomy), 
in the opinion of the Site Investigator 
6. Body weight > 5th percenti le for age using CDC guidelines 
7. Medical care meets and is expected to continue to meet guidelines set out in the 
Consensus Statement for Standard of Care in SMA ( Wang et al. 2007), in the opinion of 
the Site Investigator  
8. Gestational age of 35 to 42 weeks and gestation body weight ≥  2 kg  
9. Reside within approximately 9 hours ground- travel distance from a participating study 
center for the duration of the study.  Residence > 2 hours ground- travel distance from a 
study center must obtain clearance from the Site Investigator and the study  Medical 
Monitor 
10. Able to complete all study procedures, measurements and visits and parent or 
guardian/subject has adequately supportive psychosocial circumstances, in the opinion of 
the Site Investigator  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
25  5.2 Exclusion Criteria  
Subjects meeting any of the following criteria are not eligible for the study:  
1. Hypoxemia (O 2 saturation awake < 96% or O 2 saturation asleep < 96%, without 
ventilation support) 
2. Presence of an untreated or inadequately treated active infection requiring systemic 
antiviral or antimicrobial therapy at any time during the screening period  
3. History of brain or spinal cord disease that would interfere with the LP procedures, CSF 
circulation, or safety assessments  
4. Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter  
5. History of bacterial meningitis  
6. Clinically significant abnormalities in hematology or clinical chemistry parameters, as 
assessed by the Site Investigator, at screening that would render the subject unsuitable for 
inclusion 
7. Treatment with another investigational drug (e.g., albuterol, riluzole, carnitine, creatine, 
sodium phenylbutyrate, salbutamol, valproate, hydroxyurea, etc.), biological agent, or 
device within 90 days prior to enrollment or anytime during the study.  Any history of 
gene therapy or cell transplantation  
8. The subject’s parent(s) or legal guardian(s) is unable to understand the nature, scope, and 
possible consequences of the study, or does not agree to comply with the protocol defined schedule of assessments  
9. Ongoing medical condition that according to the Site Investigator would interfere with 
the conduct and assessments of the study.  Examples are medical disability other than 
SMA that would interfere with the assessment of safety or would compromise the ability 
of the subject to undergo study procedures 
6. STUDY PROCEDURES  
6.1 Study Schedule  
All required study procedures are outlined in Appendices A , B and C . 
6.2 Study Assessments  
6.2.1 Collection of CSF  
Subjects  will have CSF collected pre-dose during the LP procedure on Day s 1, 15, 85, 253, 379, 
505, 631, 757, 883, 1009, 1135, and 1261 for safe ty and PK analyses.  Approximately 5  mL of 
CSF will be collected by lumbar puncture, using a ‘spinal anesthesia’ needle and a stand ard LP 
collection kit.  A 22G anesthesia needle is recommended.  Depending on institutional guidelines, 
anesthesia or sedation may be used for the procedure.  Spinal ultrasound may be used for the LP 
procedure, if deemed necessary, but is not required.  CSF will be used for standard laboratory 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
26  measurement of cells, glucose, and protein, and ISIS 396443 pharmacokinetic analyses.  Extra 
CSF may be stored for investigation of possible biomarkers of SMA disease or the 
pharmacodynamic effects of ISIS 396443 (e.g., CSF mRNA, CSF protein, CSF miRNA panel) or 
for profiling of drug binding proteins, bioanalytical method validation purposes, stability 
assessments, metabolite assessments, immunogenicity assessments (including assay development 
and validation purposes), or to assess other actions of ISIS 396443 with CSF constituents . 
6.2.2 Laboratory Analytes 
Laboratory measurements of serum chemistry , hematology, urinalysis, coagulation parameters, 
and plasma antibodies to ISIS 396443 will be performed at the times shown in the Schedule of 
Procedure s (Appendix A ).  The analytes to be measured are shown in Appendix B . 
6.2.3 Neurological Examinations as A ssessed by the Hammersmith Infant Neurological 
Examination (HINE) 
Neurological examinations  will be performed using the Hammersmith Infant Neurological 
Examination (HINE).  These examinations will include assessment of mental status, level of 
consciousness, sensory function, motor function, cranial nerve function, and reflexes.  Motor 
milestones  will be accessed using Section 2 of the HINE, which is comprised of 8 independent 
milestone categories:  voluntary grasp, ability to kick in supine position, head control, rolling, 
sitting, crawling, standing, and walking.  HINE  will be performed at the t imes/dates according to 
the schedule as shown in Appendix A (Schedule of Procedures).  
6.2.4 Pharmacokinetics Specimen Collection  
Plasma and CSF specimens will be collected as shown in Appendix A (Schedule of Procedures) 
and Appendix C ( Pharmacokinetic Samp ling Schedule).  The following ISIS 396443 plasma PK 
parameters (though not necessarily limited to) will be derived when appropriate from the 
individual subject  concentration vs. time profiles using noncompartmental-based methods and 
based on actual sampli ng times : 
 T he maximal observed plasma drug concentration (C max) 
 T he time to reach C max in plasma (Tmax) 
 The area under the plasma concentrations time curve  from the time of the IT dose to the 
last collected sample  
 T he apparent terminal elimination half-life (t ½), if possible 
6.2.5 C hildren’s Hospital of Philadelphia Infant Test for Neuromuscular Disease  
(CHOP  INTEND) 
Subjects  will be evaluated using the CHOP  INTEND test  according to the schedule as shown in 
Appendix A (Schedule of Procedures).  The CHOP INTEND test was specifically designed to 
evaluate the motor skills of infants with significant motor weakness, including infants with SMA  
(Glanzman et al. 2010).  The CHOP INTEND test captures neck, trunk, proximal and distal limb 
strength in 14 e licited and 2 observational items.   The CHOP INTEND has been established as a 
safe and reliable infant motor  measure in infantile -onset SMA. 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
27  6.2.6 Hammersmith Functional Motor Scale – Expanded  
All s ubjects who have maintained a CHOP INTEND total score of ≥ 50 for 2 consecutive study 
visits will be evaluated using the Hammersmith Functional Motor Scale Expanded (HFMSE) at 
the times shown  in Appendix A  (Schedule of Procedures).  This evaluation will be performed in 
addition to the CHOP INTEND.  The HFMSE is a reliable and validated tool to assess motor 
function in children with SMA.  The scale was originally developed with 20 scored activities and 
was devised for use in children with SMA type 2 and type 3 with limited ambulation to give objective information on motor ability and clinical progression ( Main et al. 2003).   The expanded 
scale includes an additional module of 13 items developed to allow for evaluation of ambulatory SMA patients ( O’Hagen et al. 2007).  The HF MSE has been shown to be highly correlated with 
other clinical assessments and shows good test- retest reliability.  The HFMSE is easy to use and 
quickly administered. 
6.2.7 Compound M uscle Action Potential  
Measurements of Compound Muscle Action Potential ( CMAP ) will be assessed  (ulnar and 
peroneal  nerves)  according to the schedule as shown in Appendix A (Schedule of Procedures) .  
CMAP is an electrophysiological technique that can be used to determine the approximate 
number of motor neurons in a muscle or group of muscles.  CMAP is a well validated method for 
tracking disease progression in neuromuscular disorders such as spinal muscular atrophy (SMA) 
(Swoboda et al. 2005; Lewalt  et al. 2010) and amyotrophic lateral sclerosis ( Shefner  et al. 2011) 
and has  been proposed as a potential biomarker of a therapeutic effect in SMA.  
6.2.8 Growth Parameters  
Subjects will be assessed by growth measurements  according to the schedule as shown in 
Appendix A ( Schedule of Procedures) .  Growth parameters of body length, head circumference, 
chest circumference, and arm circumference will be measured.  Additional parameters of weight 
for age, weight for length, and head to chest circumference ratio will be calculated . 
6.2.9 Ventilation  Use 
The subject’s ventilator use will be recorded at  the times/dates according to the schedule as 
shown in Appendix A (Schedule of Procedures) . 
6.2.10 Phone Assessments  
Monitoring telephone calls will occur on Study D ays 8, 43, 57, 71, 106, 127, 134, 148, 189, 197, 
218, 239, 274, 295, 316, 358, 380, 400, 421, 463, 484, 506, 526, 547, 589, 610, 632, 652, 673, 715, 736, 758, 778, 799, 841, 862, 884, 904, 925, 967, 988, 1010, 1030, 1051, 1093, 1114, 1136, 1156, 1177, 1219, 1240, 1262, 1282, 1303, and 1324 (i.e., approximately every 3 weeks between 
study visits ).  Changes in concomitant medications and adverse events will be recorded.   In 
addition, information on the subject’s ventilator use  and SMA disease status will be collected.  
6.2.11 Safety Evaluations 
Safety  will be evaluated by assessment of AEs including SAEs as described in Section 9.  
Additional safety evaluations include the following parameters: 
 Neurological examination s (HINE)  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
28   Vital signs  
 Physical examinations and weight  
 Clinical laboratory tests (serum chemistry, hematology, urinalysis)  
 CSF laboratory tests ( cell count, protein, glucose) 
 E lectrocardiogram  (ECG) 
 Use of concomitant medications  
7. STUDY DRUG  
7.1 Study  Drug  
There are 2 types of Study Drug that may be provided for this study: 
a. Study Drug at a concentration of 20 mg/mL which is diluted prior to use ; this is described 
as the ‘Two-Vial’ configuration.  See Section 7.1.1 for more details.  
b. Study Drug at a concentration of 2.4 mg/mL; this is described as ‘Ready -to-Use Vial ’ 
configuration.  See Secti on 7.1.2 for more details.  
7.1.1 Two-Vial Configuration ( ISIS 396443 and D iluent ) Description  
ISIS 396443 active drug product  and artificial CSF diluent are  manufactured by Ionis 
Pharmaceuticals , Inc., Carlsbad, CA, USA.  The active drug product is supplied at a 
concentration of 20 mg/mL as a 2.5 mL fill volume in a 5 mL clear glass vial.  The diluent 
(artificial CSF) is supplied as a 20 mL fill volume in a 3 0 mL clear glass vial.  These 
configurations allow for various clinical doses by using different dilution procedures between the active drug product and diluent vials.  Study Drug characteristics are described in  Table 1 .  More 
details are provided in the Investigators Brochure.  
Table 1 Study Drug Characteristics  
Study Drug  ISIS 396443  Diluent  
(artificial CSF)  
Strength  20 mg/mL  NA 
Volume/vial  2.5 mL solution per vial  20 mL solution per vial  
Route of Administration  IT injection  IT injection  
 
ISIS 396443 and the diluent (artificial CSF) must be stored securely at 2° C to 8° C.  
ISIS 396443 must be protected from light. 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
29  7.1.2 Ready- To-Use Vial Configuration Description  
In the ‘Ready -to-use’ vial configuration, t he Study Drug is supplied in 6 mL clear glass vials at a 
concentration of 2.4 mg/mL.  The Study Drug and its storage and preparation instructions will be 
provided by the Sponsor or designee.  Study Drug characteristics are listed under Table 2. 
Table 2 Study Drug Characteristics :  Ready -To-Use Vial Configuration 
Study Drug  ISIS 396443 Drug Product  
Strength  2.4 mg/mL  
Volume/vial  5.0 mL solution per vial  
Route of Administration  IT injection  
 
ISIS 396443 must be stored securely at 2° to 8° C and protected from light. 
7.2 Packaging and Labeling  
Ionis Pharmaceuticals , Inc. will provide the Site Pharma cists with packaged Study Drug labeled 
in accordance with regulatory requirements. 7.3 Study  Drug Accountability  
The study staff is required to document receipt, dispensing and return of Study Drug supplies 
provided by the Sponsor.  Drug accountability documentation and all used and unused Study Drug  vials ( ISIS 396443 and diluent) must be returned to Ionis Pharmaceuticals , Inc. or 
designee.  
8. TREATMENT OF SUBJECTS 
8.1 Study  Drug Administration 
Each subject  will receive a single IT bolus (1-3 minute) LP injection of Study Drug  using a 
‘spinal anesthesia’ needle and 5 mL syringe.  A 2 2G spinal anesthesia needle is recommended.  
The target site f or needle insertion is the L3/L4 space, but may be 1 segment above or 
1-2 segments below this level, if needed.  P rior to the injection 5 -6 mL of CSF fluid is to be 
collected for analyses.  Depending on institutional guidelines, anesthesia or sedation may be used 
for the LP procedure, following institutional procedures.  Spinal ultrasound may be used for the 
LP procedure, if deemed necessary, but is not required. 
Table 3 outlines the dose equivalent and ISIS 396443 concentration for ISIS 396443 dose 
cohorts to be delivered during the ‘loading’ dosing treatment period (i.e., dosing on Days 1, 15 
and 85).  Study Drug  dosing during the ’loading’ dosing treatment period will be done using the 
two-vial configuration. 
Table 4 outlines the dose equivalent and ISIS 396443 concentration for ISIS 396443 to be 
delivered during the ‘maintenance’ dosing treatment period (i.e., dosing on Days 253, 379, 505, 631, 757, 883, 1009, 1135, and 1261).  Study Drug  dosing during the ‘maintenance’ dosing 
ISIS 396443-CS3A CONFIDENTIAL Amendment 6
Protocol 25 January 2016
 
30  treatment period will be done using the two-vi al configuration and w ill transition to the  
ready-to-use vial configuration once the cu rrent protocol amendment has been approved. 
Table 3 ISIS 396443 Dose Equivalents and Concentration During the ‘Loading’ 
Dosing Treatment Period 
Cohort Dose Equivalent 
(mg) Concentration 
(mg/mL) Injection Volume 
(mL) 
1 6 1.2 See Table 5 
2 12 2.4 See Table 5 
 
Table 4 ISIS 396443 Dose Equivalent and Concentration During the ‘Maintenance’ 
Dosing Treatment Period 
Cohorts Dose Equivalent 
(mg) Concentration 
(mg/mL) Injection Volume 
(mL) 
1 and 2 12 2.4 See Table 5 
 
The volume of the injection will be adjusted base d on the subject’s age.  Subjects who are older 
than 24 months (730 Days) on the day of dos ing will receive the full 12 mg dose of the 
Study Drug (5 mL).  For subjects younger than 24 months of age, the vo lume of the injection 
will be adjusted based on the subject’s age on the day of dosing per Table 5, such that each 
subject will receive a 12 mg equivalent dose based on CSF volume scaling. 
Table 5 ISIS 396443 Dose Volume to be Injected 
Age Estimated 
CSF Volume* Injection Volume 
(mL) 
0-3 months  
(0-90 days) 120 mL 4 mL 
3-6 months  
(91-182 days) 130 mL 4.3 mL 
6-12 months  
(183 – 365 days 135 mL 4.5 mL 
12-24 months  
(366 – 730 days) 140 mL 4.7 mL 
> 24 months 
(> 730 days) 150 mL 5.0 mL 
* Matsuzawa et al. 2001  
 
Please refer to the Study Drug Ma nual provided by the Sponsor fo r detailed instructions for 
Study Drug preparation and administration. 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
31  8.2 Other Protocol -Required Drugs  
There are no other protocol required drugs, but depending on institutional guidelines anesthesia 
or sedation may be used for the LP procedure, following institutional procedures.  
8.3 Other Protocol -Required Procedures  
There are no other protocol- required treatment procedures . 
8.4 Treatment Precautions  
Subjects will be encouraged to lie flat for 1 hour following dosing, if possible. 8.5 Safety Monitoring Rules 
Please refer to the Guidance to Investigator section of the Investigator Brochure. 
8.6 Stopping Rules  
Please refer to  Section 8.8.  There are no additional specific stopping rules for this study but the 
Investigator should discuss significant concerns relating to in dividual subjects with the 
Ionis Medical Monitor to ensure that it is appropriate for the subject to continue Study Drug. 8.7 Adjustment of Dose and/or Treatment Schedule  
No adjustment of dose is permitted.  In the event of a concurrent illness that would prevent the 
dosing procedure from being performed safely, an adjustment in the dose schedule may be 
permitted, but must be approved by the Sponsor Medical Monitor.  In this case, the scheduled Day 15 dosing vis it may be delayed until up to Day 70 and  the scheduled Day 8 5 dosing visit 
may be delayed up to Day 120.  The scheduled dosing visits during the ‘maintenance’ period 
(i.e., Days  253, 379, 505, 631, 757, 883, 1009, 1135, and 1261) may be delayed by up to 
8 weeks.  
8.8 Discontinuation of Study Treatment  
A subject  must permanently discontinue study treatment for any of the following: 
 The subject  withdraws consent  
 The subject  experiences an adverse event that necessitates permanent discontinuation of 
study treatment  
 The subject experiences a DLT as defined in Section 3.7 
The reason for discontinuation of study treatment must be recorded in the Case Report Form 
(CRF ) and source documentation.  
Subjects that discontinue treatment will enter the post- treatment follow-up period unless consent 
is withdrawn  (see Appendix A ). 
8.9 Withdrawal of Subjects from the S tudy  
Subjects  must be withdrawn from the study for any of the following: 
 Withdrawal of consent 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
32   The subject  is unwilling or unable to comply with the protocol 
Other r easons for withdrawal of subjects from the study might include:  
 At the discretion of the Investigator for medical reasons 
 At the discretion of the Investigator or Sponsor for noncompliance 
 Signific ant protocol deviation 
 Administrative decision by the I nvestigator or Sponsor 
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal.  All information, including the reason for withdrawal from Study, must 
be recorded in the CRF . 
Any subject who withdraws consent to participate in the study will be removed from further 
treatment and study observation immediately upon the date of request.  These subjects  should be 
encouraged to complete the earl y termination study procedures and observations at the time of 
withdrawal  (Appendix A ). 
For subjects  withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  early ter mination study procedures and observations at t he time of withdrawal 
(see Appendix A) . 
8.10 Concomitant Therapy  and Procedures  
The use of concomitant therapies or procedures defined below must be recorded on the subject’s  
CRF .  AEs related to administration of these therapies or procedures must also be documented on 
the appropriate CRF. 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered between  
screening  and last telephone contact . 
Subjects should consult with the Site Investigator or qualified designee prior to initiating any 
new medication, including non-prescription compounds or any other non- drug therapy.  
Allowed Concomitant Therapy 
Throughout the study, Site Investigators or designated licensed physicians involved in the study 
may prescribe concomitant medications or treatments deemed necessary for adverse events or to 
provide adequate supportive care. 
Disallowed Concomitant Therapy 
Study subjects are prohibited from receiving other experimental agents during the study.  This 
includes marke ted agents being used off-label and/or at experimental doses that are being tested 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
33  for the treatment of SMA.  The following agents are specifically prohibited:  valproate, riluzole, 
carnitine, creatine, sodium phenylbutyrate, hydroxyurea, salbutamol. 
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy) or diagnostic 
assessment (e.g., blood gas measurement, bacterial cultures) performed between screening and  
last visit.  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING   
9.1 Sponsor Review of Safety Information 
Safety informatio n will be collected, reviewed, and evaluated  by the Sponsor  in accordance with 
the Safety Management P lan throughout the conduct of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor is responsible for regulatory submissions and reporting to the Investigators of SAEs 
including suspected unexpected serious adverse reactions (SUSARs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH E6.  Country- specific regulatory 
requirements will be followed in accordance with local co untry regulations and guidelines. 
IRBs/REBs  will be notified of any serious adverse event ( SAE ) according to applicable 
regulations.  The DSMB  will be notified of any SAE as specified in the DSMB  charter.  
The Sponsor will evaluate the available information and decide if there is a reasonable possibility 
that the Study Drug  caused the AE  and, therefore, meets the definition of a SUSAR. 
For the purpose of regulatory reporting of SUSARs, there are no “expected” AEs  in this study 
population.  For Study Drug “expected” AEs , refer to the Investigator Brochure.  
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign (including a clinically significant 
abnormal laboratory finding, for example), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any adverse event caused by the Study Drug . 
A suspected adverse reaction  is any adverse event for which there is a reasonable possibility that 
the drug caused the adverse event.  A suspected adverse reaction implies a lesser degree of certainty ab out causality than an adverse reaction. 
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event  that in the view of either the Investigator or 
Sponsor, meets any of the following criteria:  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
34   Results in death  
 Is life threatening: that is, poses an immediate risk of death at the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of 
either the Investigator or Sponsor, its occurrence places the subject at immediate risk of 
death.  It does not include an AE  or suspected adverse reaction that , had it occurred in a 
more severe form, might have caused death. 
 Requires inpatient hospitalization or prolongation of existing hospitalization  
Hospitalization is defined as an admission of greater than 24 hours to a medical facility 
and does not always qualify as an AE  
 Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
 Results in congenital anomaly or birth defect in the  offspring of the subject  (whether the 
subject  is male or female)  
 Important medical events  that may not result in death, are not life -threatening, or do not 
require hospitalization may also be considered serious when, based upon appropriate medical judgmen t, they may jeopardize the subject and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events includ e allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalization , or the development of drug dependency or drug abuse. 
9.4 Monitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a subject  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as AEs unless the pre-existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.1 Serious Adverse Events  
In the interest of subject safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to Study Drug ) should be reported to the Sponsor  within 
24 hours of the Study Center’s first knowledge of the event.  The collection of SAEs will begin after the subject signs the informed consent form and stop at the end of the subject’s  follow-up 
period which is defined as the subject’s last visit.  When  the Investigator is reporting by 
telephone, it is important to speak to someone in person versus leaving a message.  An Initial 
Serious Adverse Event Form should be completed and a copy should be faxed to the Sponsor . 
Detai led information should be actively sought and included on Follow-Up Serious Adverse 
Event Forms as soon as additional information becomes available.  All SAEs will be followed 
until resolution.  SAEs that remain ongoing past the subject’s  last protocol-spe cified follow -up 
visit will be evaluated by the  Investigator and Sponsor.  If the Investigator and Sponsor agree the 
subject’s condition is unlikely to resolve, the Investigator and Sponsor will deter mine the follow -
up requirement. 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
35  9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the subject  signs the informed consent form 
and will stop at the end of the subject’s  follow- up period, which is defined as subject’s last visit.  
The Investigator will monitor each  subject closely and record all observed or volunteered AEs on 
the Adverse Event Case Report Form . 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opinion of the following should be documented on the Adverse Event Case 
Report Form: 
9.4.3.1 Relationship to the Study Drug  
The event’s relationship to the Study Drug  is characterized by one of the following:  
 Related:   There is clear evidence that the event is related to the use of Study Drug  
e.g., confirmation by positive re- challenge test  
 Possible:   The event cannot be explained by the subject’s  medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and Study Drug  administration  
 Unlikely/Remote:  An event for which an alternative ex planation is more likely 
(e.g.,  concomitant medications or ongoing medical conditions) or the temporal 
relationship to Study Drug  administration and/or exposure suggests that a causal 
relationship  is unlikely (For reporting purposes, Unlikel y/Remote will be grouped 
together with Not Related)  
 Not Related:   The event can be readily explained by the subject’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and Study Drug  
9.4.3.2 Severity  
The event’s severity is characterized by one of the following:  
 Mild:   The event is easily tolerated by the subject and does not affect the subject’s usual 
daily activities  
 Moderate:   The event causes the subject  more discomfort and interrupts the subject’s 
usual daily activities  
 Severe:   The event is incapacitating and causes considerable interference with the 
subject’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
36  9.4.3.3 Action Taken with Study Drug  
Action taken with Study Drug  due to the event is characterized by one of the following. 
 None:  No changes were made to Study Drug  administration and dose 
 Permanently Discontinued:   Study drug was discontinued and not restarted 
 Temporarily Interrupted, restarted – same dose:   Dosing was temporarily interrupted 
or delayed due to the AE and restarted at the same dose 
9.4.3.4 Treatment Given for Adverse Event  
Any treatment  (e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form  (treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  CRF  as appropriate).  
9.4.3.5 Outcome of the Adverse Event  
If the event is a non -serious AE then t he event’s outcome is characterized by one of the 
following: 
 AE Persists:   Subject terminates from the trial and the AE continues 
 Recovered:   Subject recovered completely from the AE  
 Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
 Change in Severity (if applicable):   AE severity changed  
If the event is a SAE then the event’s outcome is characterized by one of the following: 
 Ongoing:   SAE continuing 
 Persists (as non -serious AE):   Subject has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non-serious AE electronic 
case report form (eC RF) (the SAE resolution date should be entered as the date of onset 
of that AE) 
 Recovered:   Subject recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
 Fatal:   Subject died (the date of death should be entered as the SAE resolution date) 
9.5 Procedures for Handling Special Situations  
9.5.1 Abnormalities of Laboratory Tests 
Clinically significant abnormal laboratory test results may, in the opinion of the Investigator, 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
37  that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically significant abnormalities will be monitored by the Investigator until the parameter returns to its baseline value or until agreement is reached between the Investigator and Ionis Medical Monitor.  Laboratory abnormalities deemed not clinically significant (NCS) by the Investigator should not be reported as AEs.  Similarly, laboratory abnormalities reported as AEs 
by the Investigator should not be deemed NCS on the laboratory sheet.  
The Investigator is responsible for reviewing and signing all laboratory reports.  The signed clinical laboratory reports will serve as source documents. 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered 
an SAE, even if the subject is hospitalized; the Study Center  must document all of the following:  
 The prescheduled or elective procedure or routinely scheduled t reatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the subject’s  consent to 
participate in the study  
 The condition that required the prescheduled or elective procedure or routinely scheduled 
treatment was present before an d did not worsen or progress in the opinion of the 
Investigator between the subject’s  consent to participate in the study and the timin g of the 
procedure or treatment  
 The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reaso n for the intervention or hospital admission 
9.5.3 Dosing Errors  
Study Drug  dosing errors should be documented as Protocol Deviations.  A brief description 
should be provided in the deviation, including whether the subject  was symptomatic (list 
symptoms) o r asymptomatic, and the ev ent accidental or intentional.  
Dosing details should be captured on the Dosing CRF .  If the subject  takes a dose of Study Drug  
that exceeds protocol specifications and the subject  is symptomatic, then the symptom(s) should 
be documented as an AE and be reported per Section 9.4. 
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact the Sponsor within 24 hours. 
10. STATISTICAL CONSIDERATIONS  
10.1 Study Endpoints  
10.1.1 Primary Endpoint 
 Achievement of motor milestones as evaluated by  Module 2 of the Hammersmith Infant 
Neurological Examination   
ISIS 396443-CS3A CONFIDENTIAL Amendment 6
Protocol 25 January 2016
 
38  10.1.2 Secondary Endpoints 
The efficacy of multiple doses of ISIS 396443 as assessed by: 
 Event-free survival determined by the proportion of subjects who are alive and do not 
require permanent ventilatory support (defined as tracheostomy or the need for 
≥ 16 hours ventilation/day continuously for at least 14 days in the absence of an acute 
reversible illness) 
 Improvement in muscle strength as measured by the Children’s Hospital of Philadelphia 
Infant Test for Neuromuscular Disease (CHOP INTEND) 
 Improvement in neuromuscular electrophysiology measured by the Compound Muscle Action Potential (CMAP) of th e ulnar and peroneal nerves 
The safety and tolerabili ty of multiple doses of ISIS 396443 as assessed by: 
 Adverse events 
 Neurological examinations 
 Vital signs 
 Physical examinations and weight 
 Clinical laboratory tests (serum chemistry, hematology, urinalysis) 
 CSF laboratory tests (cell count, protein, glucose) 
 ECGs 
 Use of concomitant medications 
CSF and plasma PK of ISIS 396443. 
10.1.3 Exploratory Endpoints 
The following efficacy evaluations will be performed as exploratory endpoints: 
 Measures of respiratory stat us (number of respiratory ev ents, respiratory infections, 
respiratory-related hospitaliz ations, ventilator use, O
2 saturation awake) 
 Growth parameters (weight for age/length, h ead circumference, chest circumference, 
head to chest circumference ratio, arm circumference) 
10.2 Sample Size Considerations There is no statistical rationale for the selected sample size of 4 treated subjects in Cohort 1 and 
4 to approximately 16 subjects in Cohort 2.  The sample size was selected to ensure that the 
safety and tolerability of ISIS 396443 will be adequately assessed while minimizing unnecessary 
subject exposure rather than  statistical considerations  for the efficacy endpoints. 
ISIS 396443-CS3A CONFIDENTIAL Amendment 6
Protocol 25 January 2016
 
39  10.3 Populations 
Safety Population:  All subject s who are registered and receive at least one dose of Study Drug. 
Pharmacokinetic Population:  All subjects who are registered and for which there is at least one 
evaluable post-dose pharmacokinetic sample. 
Efficacy Population: all subjects who are registered, receive all scheduled loading doses of Study 
Drug (i.e., Days 1, 15 and 85), and complete the Day 92 visit. 
10.4 Interim Analysis 
Interim efficacy and safety analyses will be performed to provide content for regulatory 
submissions and to support ISIS 396443 drug development planning and business activities. 
Details of the analyses are containe d in the Statistical Analysis Plan. 
10.5 Planned Methods of Analysis 
10.5.1 Demographic and Baseline Characteristics 
Demographic and baseline charac teristics will be summarized de scriptively for each dose cohort. 
10.5.2 Efficacy Analysis 
The primary analysis will include the proportion of subjects who achieved improvement in motor 
milestones at their last visit.  It wi ll be tabulated by cohort and overall. 
Motor milestones will be accessed using Section 2 of the Hammersmith Infant Neurological 
Exam (HINE) which is comprised of 8 indepe ndent milestone categories:  voluntary grasp, 
ability to kick in supine position, head control,  rolling, sitting, crawling, standing, and walking.  
Within each of these categories, subjects can progress from complete inability to perform a 
motor task, for example no grasp, no kicking, inabili ty to maintain head upright, all the way to 
complete mastery of each category, for example achievement of pincer grasp, touching toes 
while supine, or maintaining their head upright. 
Event-free survival will be evaluated by determin ing a proportion of subjects who are alive and 
do not require permanent ventilatory support.  Pe rmanent ventilation is defined as tracheostomy 
or the need for ≥ 16 hours ventilation/day continuously for at least 14 days in the absence of an 
acute reversible illness. 
The CHOP INTEND infant motor function scale to tal score, change, and percent change from 
baseline will be summarized by c ohort and overall, and by visit. 
The absolute values for CMAP amplitude and CMAP area, as well as absolute and percent 
changes from baseline, will be summarized by cohort and overall, and by visit. 
Full details of the methodology for analyses described above, as well as all additional analyses, 
are contained in the Statistical Analysis Plan. 
10.5.3 Safety and Pharmacokinetic Analysis 
All subjects exposed to ISIS 396443 will be  included in the safety analyses. 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
40  Treatment duration and amount of Study Drug  received will be summarized by dose cohort.  
Subject incidence rates of all adverse events will be tabulated by Medical Dictionary for 
Regulatory Activities ( MedDRATM) system organ class, and by MedDRATM term.  Tables and/or 
narratives of “on -study” deaths, serious and significant adverse events, including early 
withdrawals due to adverse events, will also be provided. 
All treatment emergent AEs, all treatment emergent AEs potentially related to Study Drug, all 
treatment emergent serious AEs, and all treatment emergent serious AEs potentially related to 
Study Drug will be summarized.  
Laboratory tests including chemistry panel, complete blood count with differential, urina lysis, 
and CSF components will be summarized by study visit for each dose cohort.  These safety 
variables will also be presented over time after Study Drug administration, as appropriate, using 
results prior to Day 1 dosing as Baseline.  Vital sign results will be presented similarly.  
Physical and neurological examination findings and results from ECG will be listed for review.  
As appropriate, results will also be summarized descriptively for each dose cohort.  Concomitant medication usage for each subject  will be listed for review.   Plasma pharmacokinetic parameters 
and ISIS 396443 concentrations in plasma and CSF for the P harmacokinetic population will be 
summarized by dose cohort using descriptive statistics  and, where warranted, presented 
graphically.  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent documents should be prepared in the language(s) of the potential subject population, based on an English version provided by the Sponsor and should be easy to 
under stand . 
Before a subject’s  participation in the trial, the Investigator is responsible for obtaining written 
informed consent from the parent or legal guardian after adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study and before any protocol- specific 
screening procedures or an y Study Drug s are administered.  Sufficient time must be given to 
consider whethe r to participate in the study.  
The acquisition of informed consent and the parent/legal guardian’ s agreemen t or refusal of 
his/her notification of the primary care physician  should be documented in the subject’s medical 
records, and the informed consent form(s) should be signed and personally dated by the parent/legal guardian  and by the study person who conducted the informed consent discussion.  
The original signed informed consent form (s) should be retained in  the Study Master File and in 
any other locations required by institutional policy , and a copy of the signed consent form(s) 
should be provided to the parent or guardian . 
11.2 Ethical Conduct of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated October  2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
as well as the dem ands of national drug and data protection laws and other applicable regulatory 
requirem ents will be strictly followed.  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
41  11.3 Institutional Review Board /Research Ethics Board  
A copy of the protocol, proposed informed consent form, other written subject  information, and 
any proposed advertising material must be submitted to the IRB/REB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received b y the 
Sponsor before recruitment of subjects into the study and shipment of Study Drug .  A copy of the 
written approval of any other items/materials that must be approved by the Study Center  or 
IRB/REB  must also be received by the Sponsor before recruitment of subjects into the study and 
shipment of Study Drug .  The Investigator’s Brochure must be submitted to the IRB/REB  for 
acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the IRB/REB  for all 
subsequent protocol amendments and changes to the informed consent documents.  The 
Investigator should notify the IRB/REB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2.  The Investigator should also notify the IRB/REB  of serious adve rse events 
occurring at the Stu dy Center  and other adverse event reports received from the Sponsor, in 
accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IRB/REB  approval/renewal throughout 
the duration of the study.  Copies of the Investigator’s reports , all IRB/REB  submissions and the 
IRB/REB  continuance of approval must be sent to the Sponsor. 
11.4 Subject Confidentiality  
The Investigator must ensure that the subject’s  confidentiality is maintained.  On the CRF s or 
other documents submitted to the Sponsor, subjec ts should be identified by unique initials and a 
subject  study number only.  Documents that are not for submission to the Sponsor ( e.g., signed 
informed consent /assent  forms) should be kept in strict confidence by the Investigator. 
In co mplia nce with federal and local regulations/ICH GCP Guidelines, it is  required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IRB/REB  direct access to review the subject’s original medical records for 
verification of study- related procedures and  data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the study.  The Investigator is obligated to inform and obtain the consent of the subject ’s parent or 
guardian to permit named representatives to have access to his/her study-related records without 
violating the confidentiality of the subject. 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.1 Prot ocol Amendments  
Protocol amendments must be made only with the prior approval of the Sponsor.  Agreement 
from the Investigator must be obtained for all protocol amendments and amendments to the 
informed consent document.  The regulatory authority and IRB/REB  must be informed of all 
amendments and give approval for any amendments likely to affect the safety of the subjects or the conduct of the trial.  The Investigator must  send a copy of the approval letter from the 
IRB/REB  to the Sponsor. 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
42  12.2 Study Term ination 
Both the Sponsor  and the Investigator reserve the right to terminate the study, according to the 
terms of the study contract.  The Investigator/Sponsor should notify the IRB/REB  in writing  of 
the trial’s completion or early termination.  
12.3 Study Documentation and Storage 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the subject’s CRF  data 
are obtained.  These include but are not limited to hospital records, clinical and office charts, 
laboratory and pharmacy records, imaging , and correspondence.  In this study, CRFs may not be 
used as so urce documents. 
The Investigator and S tudy Center staff is  responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section 8  of the ICH Guidelines (E6), suitable for inspec tion at any time by representatives from 
the Sponsor and/or applicable r egulatory authorities.  Elements should include: 
 Subject files containing completed CRF s, informed consents, and supporting copies of 
source documentation 
 Study files containing the protocol with all amendments, Investigator’s Brochure , copies 
of pre -study documentation and all correspondence to and from the IRB/REB  and the 
Sponsor 
 If drug supplies are maintained at the Study Center , proof of receipt, Study Drug Product 
Accountability Record, Return of Study Drug Product for Destruction, and all drug-
related correspondence  
In addition, all original source documents supporting entries in the CRF s must be maintained and 
be readily available.  
No study document should be destroyed without prior written agreement between the Sponsor  
and the Investigator.  Should the Investigator wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor . 
12.4 Study Monitoring  
The Sponsor representative and regulatory authority inspectors are responsible for contacting and 
visiting the Investigator for the purpose of inspecting the facilities and, upon request, inspecting 
the various records of the trial (e.g., CRF s and other pertinent data) provided that subject  
confidentiality is respected.  
The Sponsor monitor is responsible for inspecting the CRF s at regular intervals throughout the 
study to verify adherence to the protocol; completeness, accuracy, and consistenc y of the data; 
and adherence to local regulations on the conduct of clinical research.  The monitor should have 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
43  access to subject  medical records and other study- related records needed to verify the entries on 
the CRF s. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the 
course of these monitoring visits, including delays in completing CRF s, are resolved.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit 
by representatives from the Sponsor’s Clinic al Quality Assurance Department. Inspection of 
Study Center  facilities (e.g., pharmacy, drug storage areas, laboratories) and review of study-
related records will occur to evaluate the trial conduct and compliance with the pr otocol, ICH 
GCP, and applicable regulatory requirements. 
To ensure the quality of clinical data a clinical data management review will be performed on 
subject  data received by the Sponsor.  During this review, subject data will be checked for 
consistency, omissions, and any apparent discrepancies.  In addition, the data will be reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be sent to the 
Study Center  for completion and return to Sponsor. 
The Principal Investigator will sign and date the indicated places on the CRF .  These signatures 
will indicate that the principal Investigator inspected or reviewed the data on the CRF , the data 
queries, and the Study Center  notifications, and agrees with the content. 
12.5 Language 
CRF s must be completed in English.  Generic names for concomitant medications should be 
recorded in English if possible, unless it is a combination drug, then record the trade name in 
English. 
All written information and other material to be used by subjects  and investigative staff must use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insuran ce coverage for clinical trials and will follow 
applicable local compensation laws.   Subjects  will be treated a nd/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for 
Injury section of the Informed Consent document. 
  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
44  13. REFERENCES  
Campbell SK, Swanlund A, Smith E, et al. Validity of the TIMPSI for estimating concurrent performance on the test 
of infant motor performance. Pediatric  Phys ical Ther apy 2008 Spring; 20: 3 -10. 
Cho S, Dreyfuss G. A degron created by SMN2 Exon 7 skipping is a principal contributor to spinal muscular 
atrophy severity. Genes Dev  2010; 24: 438- 442. 
Coovert DD, Le TT, McAndrew PE, et al . The survival motor neuron protein in spinal muscular atrophy. Hu m Mol 
Genet 1997; 6: 1205- 1214.  
Feldkotter M, Schwarzer V, Wirth R, et al. Quantitative analyses of SMN1 and SMN2 based on real -time light 
cycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum 
Genet 2002; 70: 358- 368. 
Finkel RS, Hynan LS, Glanz man AM, et al; AmSMART Group. The test of infant motor performance: reliability in 
spinal muscular atrophy type I. Pediatric Physical Therapy  2008 Fall; 20: 242- 246. 
Geary RS, Yu RZ, Watanabe T, et al . Pha rmacokinetics of a tumor necrosis factor -α phosphorothioate 2′ -O-(2-
Methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Disp 2003; 31: 1419- 1428.  
Glanzman AM, Mazzone E, Main M, et al . The Children’s Hospital of Philadelphia Infant Test of Neuromuscular 
Disorders (CHOP INTEND): Test development and reliability . Neurom uscular Disorders  2010; 20: 155- 161. 
Helmken C, Hofmann Y, Schoenen F, et al. Evidence for a modifying pathway in SMA discordant families: reduced 
SMN level decreases the amount of its interacting partner and Htra2 -beta1. Hum Genet 2003; 114: 11- 21. 
Henry S, Stecker K, Brooks D, et al . Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice. J Pharmacol Exp Ther 2000; 292: 468- 479. 
Henry SP , Johnson M, Zanardi TA, et al. Renal uptake and tolerability of a 2 ′-O-methoxyethyl modified antisense 
oligonucleotide (ISIS 113715) in monkey. Toxicology 2012; 301: 13-20. 
Hua Y, Vickers TA, Baker BF, et al . Enhancement of SMN2 Exon 7 inclusion by antisense oligonucleotides 
targeting the exon. PLoS Biol 2007; 5: e73.  
Hua Y, Vickers TA, Okunola HL, et al. Antisense masking of an HnRNP A1/A2 intronic splicing silencer corrects 
SMN2 splicing in transgenic mice. Am J Hum Genet  2008; 82: 834- 848. 
Keren H , Lev -Maor G, Ast G. Alternative splicing and evolution: diversification, exon definition and function. 
Nat.Rev.Genet 2010; 11: 345- 355. 
Le TT, Pham LT, Butchbach ME, et al . SMN Δ7, the major product of the centromeric survival motor neuron 
(SMN2) gene, ext ends survival in mice with spinal muscular atrophy and associates with full -length SMN. Hum 
Mol Genet 2005; 14: 845- 857. 
Lee LCY, Sennett M, Erickson JM. Prevention and management of post -lumbar puncture headache in pediatric 
oncology patients. J Ped Onc Nurs 2007; 24: 200- 207. 
Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy -
determining gene. Cell 1995; 80: 155- 165. 
Lefebvre S, Burlet P, Liu Q, et al. Correlation between severity and SMN protein le vel in spinal muscular atrophy. 
Nat Genet 1997; 16: 265- 269. 
Lewalt AJ, Krosschell KJ, Scott C, et al. Compound muscle action potential and motor function in children with 
spinal muscular atrophy. Muscle Nerve 2010; 42(5); 703- 708. 
Main M, Kairon H, Mercur i E, Muntoni F. The Hammersmith Functional Motor Scale for children with spinal 
muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr 
Neurol 2003; 7(4): 155- 159. 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
45  Matsuzawa J, Matsui  M, Konishi T,  et al. Age -related volumetric changes of brain gray and white matter in healthy 
infants and children. Cereb Cortex  2001 Apr;  11(4):335-3 42. 
McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense 
oligonucleot ide inhibitor of human protein kinase C -α expression. J Bio Chem 1999; 274: 1715- 1722.  
O’Hagen JM, Glanzman AM, McDermott MP, et al . An expanded version of the Hammersmith Functional Motor 
Scale for SMA II and III patients.  Neuromuscular Disorders 2007; 17: 693- 697. 
Passini MA, Bu J, Richards AM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms 
of severe spinal muscular atrophy. Science Trans Med 2011; 3: 1 -12. 
Prior TW, Swoboda KJ, Scott HD, Hejmanowski AQ. Homozygous SMN1 deletions in unaffected family members 
and modification of the phenotype by SMN2 gene. Am J Med Genet 2004; 130A: 307- 310. 
Shefner JM, Watson ML, Simionescu L, et al. Multipoint incremental motor unit number estimation as an  outcome 
measure in ALS. Neurology 2011; 77: 235- 241. 
Swoboda KJ, Prior TW, Scott CB, et al. Natural history of denervation in SMA: relation to age, SMN2 copy 
number, and function. Annals of Neurology 2005; 57: 704- 712. 
Wang CH, Finkel RS, Bertini ES, et a l; Participants of the International Conference on SMA Standard of Care. 
Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol  2007; 22:1027- 1049.  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
46   
  
 
  
 
14. APPENDICES  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
47  
  
 
  
 
Appendix A  Schedule of Procedures 
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
48 Appendix A – Schedule of Procedures  for ‘Loading’ Dosing Period , Visits Only* 
* Note that monitoring telephone calls will also occur on Study D ays 8 (±1), 43 (±2), 57 (±2), 71 (±2), 106 (±3), 
127 (± 3), 134 (±3), 148 (±3), 189 (±3), 197 (± 3), 218 (±3), 239 (±3) (i.e., every 2-3 weeks throughout the study)13 
Study Period  Screen  Dosing  
Study Day  D -21 
to 
D -1 D1 
Injection  D2 D15 ( ±1D) 
Injection  D16 D29 
(±1D) D85 ( ±2D) 
Injection  D86 
 D92 
(±1D)  D169  
(±5D)  
Pre- 
dose  LP Post-  
dose  Pre- 
dose  LP Post-  
dose  Pre- 
dose  LP Post-
dose  
Study Drug:  LP 
Injection10   X    X9     X9     
In-Patient Stay  
(24 hours)     X             
Informed Consent  X                
Inclusion/Exclusion 
Criteria X                
Medical History  X                
SMN Genetics1           X      
Vital Signs2 X X  4X3 X5 X  4X3 X X X  4X3 X X X 
Weight  X X   X    X X X   X X X 
Growth Parameters4 X         X     X X 
Physical Examination  X X    X    X X    X X 
Ventilator Use  X X    X    X X    X X 
Neurological Examination  X X  2X6 X5 X  2X6 X X X  2X6 X X X 
ECG  X         X     X  
Safety Labs7, 12 X         X     X X 
Coagulation Labs  X                
Immunogenicity   X         X     X 
CSF Safety12  X    X     X      
CSF PK11  X    X     X      
Plasma  PK11  X  3X X      X  X  X  
CHOP  INTEND  X8         X     X X 
CMAP  X8         X     X X 
Con Med Recording  X X X X X X X X X X X X X X X X 
Adverse Event Collection  X X X X X X X X X X X X X X X X 
1 Only for those patients who do not have documented evidence of SMN genetics from Athena Diagnostics  
2 Resting blood pr essure, pulse, respiratory rate, temperature, and pulse oximetry  awake.  Pulse oximetry asleep will 
also be assessed at screening  only 
3 Vita l signs performed 1, 2, 4, 6 hours after dosing  
4 L ength, weight for age/length, head circumference, chest circumference, head to chest circumference ratio, arm 
circumferenc e 
5 Conducted within 20- 24 hours after dosing  
6 Neurological exams at 3 and 6 hours after dosing  
7 Serum chemistry, hematology, urinalysis panels (see Appendix B  for analytes) .  Cystatin C will not be analy zed at 
Day 29 due to blood volume limitations  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6   
Protocol   25 January 2016  
 
49 Appendix A – Schedule of Procedures for ‘Loading’ Dosing Period, Visits Only* Continued  
Legend Text Continued  
8 CMAP  and CHOP  INTEND assessments  do not form part of the screening assessment or inclusion/exclusion criteria 
but are baseline measurements taken during the screening phase of the study  
9 Overnight stay is optional on Day 15 and Day 85, if needed due to complications of the LP procedure  
10 Injections may not be scheduled within 72 hours  after an immunization  
11 Refer to Appendix C  for PK sampling schedule  
12 Refer to Appendix B  for analytes  
13 At telephone contact, changes in concomitant medications and adverse events will be recorded as well as information 
on the subject’s ventilator use and SMA disease status  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6  
Protocol   25 January  2016  
 
50 Appendix A – Schedule of Procedures for ‘Maintenance’ Dosing Period, Visits Only*  
* Note that monitoring telephone calls will also occur on Study D ays 274 ( ±3), 295 ( ±3), 316 ( ±3), 358 (±3), 
400 (± 3), 421 (±3), 463 (±3), 484 (±3), 526 ( ±3), 547 ( ±3), 589 ( ±3), 610 ( ±3), 652(± 3), 673 (±3), 715 ( ±3), 
736 (± 3), 778 ( ±3), 799 ( ±3), 841 (±3), 862 ( ±3), 904 ( ±3), 925 ( ±3), 967 ( ±3), 988 ( ±3), 1030 ( ±3), 1051 ( ±3), 
1093 ( ±3), 1114 ( ±3), 1156 ( ±3), 1177 ( ±3), 1219 ( ±3), 1240 ( ±3), 1282 ( ±3), 1303 ( ±3), and 1324 ( ±3) (i.e., 
approximately every 3 weeks)10 
Study Period  Dosing/Followup  
Study Day  D253  
Injection  
(±7D)  D254  D337  
(±7D)  D379, 505 , 631 , 757, 
883, 1009, 1135, and 
1261 Injection  
(±7D)  D380, 
506, 
632,7
58, 
884, 
1010, 
1136, 
1262  D442, 
568, 694, 820, 
946, 
1072, 
1198  
(±7D)  D1352  
(±7D) 
or 
Early 
Termination  
(ET) Pre- 
dose  LP Post-  
dose  Pre-
dose  LP Post-
dose  
Study Drug: LP  Injection7  X6     X6     
Vital Signs1 X  4X2 X X X  4X2  X X 
Weight  X    X X    X X 
Growth Parameters3 X11    X X11    X X 
Physical Examination  X    X X    X X 
Ventilator Use  X    X X    X X 
Neurological Examination  X  2X4 X X X  2X4  X X 
ECG      X     X12 X 
Safety Labs5, 9 X11    X     X X 
Immunogenicity13 X11    X     X X 
CSF Safety9 X     X      
CSF PK8 X     X      
Plasma  PK8 X11     X11     X 
CHOP  INTEND  X11    X X11    X X 
HFMSE14      X11    X X 
CMAP  X11    X     X X 
Phone Contact          X   
Con Med Recording  X X X X X X X X X X X 
Adverse Event Collection  X X X X X X X X X X X 
1 Resting blood pressure, pulse, respiratory rate, temperature, and pulse oximetry awake  
2 Vital signs performed 1, 2, 4, 6 hours after dosing  
3 Length, weight for age/length, head circumference, chest circumference, head to chest circumference ratio, arm 
circumference  
4 Neurological exams at 3 and 6 hours after dosing  
5 Serum chemistry, hematology, urinalysis panels (see Appendix B  for analytes)  
6 Overnight stay is optional on Days  253, 379, 505, 631, 757, 883, 1009, 1135, and 1261 if needed due to 
complications of  the LP procedure  
7 Injections may not be scheduled within 72 hours after an immunization  
8 Refer to Appendix C  for PK sampling schedule  
9 Refer to Appendix B  for analytes  
10 At telephone contact, changes in concomitant medications and adverse events will be recorded as well as 
information on the subject’s ventilator use and SMA disease status  
11 These assessments can be performed up to 7 days prior to dosing, if necessary  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6  
Protocol   25 January  2016  
 
51 Appendix A – Schedule  of Procedures for ‘Maintenance’ Dosing Period, Visits Only* 
Continued  
Legend Text Continued  
12 ECG should be performed on Day 568 only 
13 Immunogenicity assessments will be performed as deemed necessary on samples collected on other days  
14 All subjects who have  maintained a CHOP INTEND total score of ≥ 50 for 2 consecutive study visits will be 
evaluated using the Hammersmith Functional Motor Scale  Expanded (HFMSE)  in addition to CHOP INTEND  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6  
Protocol   25 January  2016  
 
52  
  
 
  
 
Appendix B  Laboratory Analytes 
 
  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6  
Protocol   25 January  2016  
 
53 Appendix B  Laboratory Analytes 
CLINICAL SAFETY ASSESSMENTS 
(minimum requirements)  OTHER ASSESSMENTS 
Clinical Chemistry  
Sodium  
Potassium  
Chloride  
Total protein  
Albumin  
Calcium  
Phosphorus  
Bicarbonate  
Glucose  
BUN 
Creatinine  
Cystatin C  
Total serum Bilirubin  
Alkaline phosphatase  
AST (SGOT) ALT (SGPT) CPK 
 
Coagulation  
aPTT PT INR  
Immunogenicity Evaluation  
ISIS 396443 plasma Abs  
 
CSF Safety (Minimum 
Requirements)  
Red blood cells  
White blood cells  
Glucose  
Protein  Urinalysis  
Specific gravity  
pH 
Protein Glucose  
Ketones  
Bilirubin  
Blood  
Red blood cells  
White blood cells  
Epithelial cells  
Bacteria  
Casts  
Crystals  
 
Hematology  
Red blood cells  
Hemoglobin  
Hematocrit  
Platelets  
White blood cells  
WBC Differential 
 (% and absolute)  
 Neutrophils  
 Eosinophils  
 Basophils  
 Lymphocytes  
 Monocytes  *PK 
Plasma ISIS 396443 levels  
CSF ISIS 396443 levels  
 
SMN Genetics  
SMN2 Copy Number  
SMN Gene Sequencing  
  
 
* Any of the collected PK plasma and CSF samples from the study patients may also be used for investigation of 
possible biomarkers of  SMA disease or the pharmacodynamic effects of ISIS 396443 (e.g., CSF mRNA, CSF 
protein, CSF miRNA panel) or for profiling of  drug binding proteins, bioanalytical method validation purposes, 
stability assessments, metabolite assessments, immunogenicity assessments (including assay development and 
validation purposes), or to assess other actions of ISIS 396443 w ith plasma and CSF  constituents  
 
  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6  
Protocol   25 January  2016  
 
54  
  
 
  
 
Appendix C  Pharmacokinetic Sampling Schedule 
 
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 6  
Protocol   25 January  2016  
 
55 Appendix C  Pharmacokinetic Sampling Schedule  
Treatment Period  Study Day  Timepoints  Blood  
Collection  CSF Collection  
Multiple Dose:  
LP Injection  D1 Predose  0.35 mL 0.5 mL 
1 hr 0.35 mL NA 
2 hr 0.35 mL NA 
4 hr 0.35 mL NA 
D2 24 hr  0.35 mL NA 
D15 Predose  NA 0.5 mL  
D85 Predose  0.35 mL 0.5 mL 
4 hr 0.35 mL NA 
D92 Anytime  0.35 mL NA 
D253  Predose  0.35 mL 0.5 mL 
D379  Predose  0.35 mL 0.5 mL 
D505  Predose  0.35 mL 0.5 mL 
D631  Predose  0.35 mL 0.5 mL 
D757  Predose  0.35 mL 0.5 mL 
D883  Predose  0.35 mL 0.5 mL  
D1009  Predose  0.35 mL 0.5 mL  
D1135  Predose  0.35 mL 0.5 mL  
D1261  Predose  0.35 mL 0.5 mL  
D1352/ET  Anytime  0.35 mL NA 
NA Not applicable (No Collection Scheduled)  
Details on sampling, preparation, and shipment are included in the study laboratory manual  
Any of the collected PK plasma and CSF samples from the study patients may also be used for investigation of 
possible biomarkers of SMA disease or the pharmacodynamic effects of ISIS 396443 (e.g., CSF mRNA, CSF protein, 
CSF miRNA panel) or for profiling of drug binding proteins, bioanalytical method validation purposes, stability 
assessments, metabolite assessments, immunogenicity assessments (including assay development and validation 
purposes), or to asses s other actions of ISIS 396443 with plasma and CSF constituents  
  
 
 
ISIS PHARMACEUTICALS, INC. 
 
 
ISIS  396443-CS3A  
 
A Study to Assess the Safety, Tolerability , and Pharmacokinetics of 
Multiple Doses of ISIS  396443 Delivered Intrathecally  to Patients 
with Infantile -Onset Spinal Muscular Atrophy  
 
Amendment 5  – 29 May 2015 
 
  
 
 
Sponsor:  
Isis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad, CA  92010 

PPD
ISIS 396443-CS3A CONFIDENTIAL Amendment 5
Protocol 29 May 2015
 
3   
ISIS 396443 
Isis Protocol Number ISIS 396443-CS3A 
Protocol Amendment 5 
 
Clinical Phase:  2 
A Study to Assess the Safety, Tolerability, a nd Pharmacokinetics of 
Multiple Doses of ISIS 396443 Deli vered Intrathecally to Patients 
with Infantile-Onset Spinal Muscular Atrophy 
 
Trial Sponsor: Isis Pharmaceuticals, Inc. 
2855 Gazelle Court 
Carlsbad, CA  92010 
Phone: + 01 760 931 9200 
Fax: + 01 760 603 2700 
Key Sponsor Contact:  
 
 
Phone: +  
Fax: +  
Date: 29 May 2015 
 
 
Confidentiality Statement 
This document contains confidentia l information of Isis Pharmaceuticals, Inc. that must not be 
disclosed to anyone other than th e recipient study staff and member s of the institutional review 
board or authorized regulatory agencies.  This information cannot be used for any purpose other 
than the evaluation or conduct of the clinical investig ation without the prior written consent of 
Isis Pharmaceuticals, Inc. 
PPD
PPD
PPD
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 5   
Protocol   29 May 2015  
 
4  Protocol  Signature Page 
 
Protocol Number:  ISIS 396443- CS3A 
Protocol Title:  A Study to Assess the Safety, Tolerability , and Pharmacokinetics  of 
Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients with 
Infantile -Onset Spinal Muscular Atrophy 
Amendment:  Amendment 5 
Date:  29 May 2015  
 
I hereby acknowledge that I have read and understand the attached clinical protocol, entitled “ A 
Study to Assess the Safety, Tolerability , and Pharmacokinetics  of Multiple Doses of ISIS 396443 
Delivered Intrathecally to Patients with Infantile -Onset Spinal Muscular Atrophy” , dated 
29 May  2015, and agree to conduct the study as described herein. 
I agree to comply with the International Conference on Harmonization  Tripartite Guideline on 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Isis Pharmaceuticals, Inc.  
 
 
 
   
Investigator’s Signature  
   
Investigator’s Name (please print)   Date (DD Month YYYY)  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 5   
Protocol   29 May 2015  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENT .......................................................................................................9  
PROTOCOL SYNOPSIS  ............................................................................................................10  
STUDY GLOSSARY ...................................................................................................................14  
1. OBJECTIVES  .....................................................................................................................16  
1.1 Primary Objective  .....................................................................................................16  
1.2 Secondary Objective .................................................................................................16  
1.3 Exploratory Objective ...............................................................................................16  
2. BACKGROUND AND RATIO NALE  ..............................................................................16  
2.1 Spinal Muscular Atrophy ..........................................................................................16  
2.2 Therapeutic Rationale  ...............................................................................................17  
2.3 ISIS 396443 ..............................................................................................................18  
2.3.1  Mechanism of Action  ...............................................................................18  
2.3.2  Chemistry  .................................................................................................18  
2.3.3  Preclinical Experience  ..............................................................................18  
2.3.4  Clinical Experience ..................................................................................19  
2.4 Rationale for Dose and Schedule of Administration ................................................20  
3. EXPERIMENTAL PLAN ..................................................................................................21  
3.1 Study Design  .............................................................................................................21  
3.2 Number of Study Centers..........................................................................................21  
3.3 Number of Subjects...................................................................................................21  
3.4 Overall Study Duration and Follow-up.....................................................................21  
3.4.1  Screening  ..................................................................................................22  
3.4.2  Treatment  ..................................................................................................22  
3.4.3  Post- Treatment Follow -up ........................................................................22  
3.5 End of Study .............................................................................................................22  
3.6 Safety M onitoring and Dose Escalation ...................................................................22  
3.7 Dose Limiting Toxicity  .............................................................................................23  
4. SUBJECT ENROLLMENT ...............................................................................................23  
4.1 Screening ...................................................................................................................23  
4.2 Registration ...............................................................................................................23  
4.3 Replacement of Subjects  ...........................................................................................24  
5. SUBJECT ELIGIBILITY  ..................................................................................................24  
5.1 Inclusion Criteria  ......................................................................................................24  
5.2 Exclusion Criteria  .....................................................................................................25  
6. STU DY PROCEDURES  ....................................................................................................25  
6.1 Study Schedule..........................................................................................................25  
6.2 Study Assessments  ....................................................................................................25  
6.2.1  Collection of CSF .....................................................................................25  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 5   
Protocol   29 May 2015  
 
6  6.2.2  Laboratory Analytes  .................................................................................26  
6.2.3  Neurological Examinations  ......................................................................26  
6.2.4  Pharmacokinetics Specimen Collection  ...................................................26  
6.2.5  Children’s Hospital of Philadelphia Infant Test for Neuromuscular 
Disease (CHOP  INTEND)  .......................................................................26  
6.2.6  Hammersmith Functional Motor Scale – Expanded ................................27  
6.2.7  Compound Muscle Action Potential ........................................................27  
6.2.8  Growth Parameters  ...................................................................................27  
6.2.9  Ventilation Use  .........................................................................................27  
6.2.10  Phone Assessments ...................................................................................27  
6.2.11  Safety Evaluations  ....................................................................................27  
7. STUDY DRUG  ....................................................................................................................28  
7.1 Study Drug  ................................................................................................................28  
7.1.1  Two-Vial Configuration (ISIS 396443 and Diluent) Description ............28  
7.1.2  Ready -To-Use Vial Configuration Description  .......................................29  
7.2 Packaging and Labeling  ............................................................................................29  
7.3 Study Drug Accountability .......................................................................................29  
8. TREATMENT OF SUBJECTS .........................................................................................29  
8.1 Study Drug Administration  .......................................................................................29  
8.2 Other Protocol- Required Drugs  ................................................................................30  
8.3 Other Protocol- Required Procedures  ........................................................................31  
8.4 Treatment Precautions  ..............................................................................................31  
8.5 Safety Monitoring Rules ...........................................................................................31  
8.6 Stopping Rules ..........................................................................................................31  
8.7 Adjustment of Dose and/or Treatment Schedule ......................................................31  
8.8 Discontinuation of Study Treatment .........................................................................31  
8.9 Withdrawal of Subjects from the Study ....................................................................31  
8.10  Concomitant Therapy and Procedures ......................................................................32  
8.10.1  Concomitant Therapy ...............................................................................32  
8.10.2  Concomitant Procedures ...........................................................................33  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................33  
9.1 Sponsor Review of Safety Information.....................................................................33  
9.2 Regulatory Requirements ..........................................................................................33  
9.3 Definitions .................................................................................................................33  
9.3.1  Adverse Event  ..........................................................................................33  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ................................33  
9.3.3  Serious Adverse Event (SAE) ..................................................................33  
9.4 Monitoring and Recording Adverse Events ..............................................................34  
9.4.1  Serious Adverse Events ............................................................................34  
9.4.2  Non-Serious Adverse Events ....................................................................35  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 5   
Protocol   29 May 2015  
 
7  9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ......................35  
9.4.3.1  Relationship to the Study Drug ...................................................35  
9.4.3.2  Severity  .......................................................................................35  
9.4.3.3  Action Taken with Study Drug ...................................................36  
9.4.3.4  Treatment Given for Adverse Event  ...........................................36  
9.4.3.5  Outcome of the Adverse Event ...................................................36  
9.5 Procedures for Handling Special Situations .............................................................36  
9.5.1  Abnormalities of Laboratory Tests ...........................................................36  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments 37 
9.5.3  Dosing Errors ...........................................................................................37  
10. STATISTICAL CONSIDERATIONS  ..............................................................................37  
10.1  Study Endpoints  ........................................................................................................37  
10.1.1  Primary Endpoint .....................................................................................37  
10.1.2  Secondary Endpoint .................................................................................38  
10.1.3  Exploratory Endpoints ..............................................................................38  
10.2  Sample Size Considerations ......................................................................................38  
10.3  Populations ................................................................................................................38  
10.4  Interim Analysis  ........................................................................................................39  
10.5  Planned Methods of Analysis ...................................................................................39  
10.5.1  Demographic and Baseline Characteristics  ..............................................39  
10.5.2  Safety and Tolerability  .............................................................................39  
10.5.3  Pharmacokinetic Analysis  ........................................................................39  
10.5.4  Exploratory Biomarker and Efficacy Analysis ........................................39  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .................................................40  
11.1  Informed Consent......................................................................................................40  
11.2  Ethical Conduct of the Study ....................................................................................40  
11.3  Institutional Review Board/Research Ethics Board  ..................................................40  
11.4  Subject Confidentiality  .............................................................................................41  
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  ....................................................41  
12.1  Protocol Amendments ...............................................................................................41  
12.2  Study Termination  ....................................................................................................41  
12.3  Study Documentation and Storage ............................................................................41  
12.4  Study Monitoring ......................................................................................................42  
12.5  Language  ...................................................................................................................43  
12.6  Compensation for Injury ...........................................................................................43  
13. REFERENCES  ....................................................................................................................44  
14. APPENDICES  .....................................................................................................................46  
Appendix A  Schedule of Procedures .....................................................................47  
Appendix B  Laboratory Analytes  .........................................................................52  
Appendix C  Pharmacokinetic Sampling Schedule................................................54  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 5   
Protocol   29 May 2015  
 
8  TABLE OF TABLES 
Page 
Table 1  Study Drug Characteristics  ................................................................................... 28  
Table 2  Study Drug Characteristics:  Ready -To-Use Vial Configuration  ......................... 29  
Table 3  ISIS 396443 Dose Equivalents and Concentration During the ‘Loading’ 
Dosing Treatment Period  ...................................................................................... 30  
Table 4  ISIS 396443 Dose Equivalent and Concentration During the 
‘Maintenance’ Dosing Treatment Period  .............................................................. 30  
Table 5  ISIS 396443 Dose Volume to be Injected ............................................................. 30  
 
 
TABLE OF FIGURES 
Page 
Figure 1  ASO Therapeutic Approach for Treatment of SMA  ............................................. 17  
 
  
ISIS 396443-CS3A CONFIDENTIAL Amendment 5
Protocol 29 May 2015
 
9  PROTOCOL AMENDMENT 
 
Protocol Number:  ISIS 396443-CS3A 
Protocol Title: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of 
Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients with Infantile-Onset Spinal Muscular Atrophy
 
Amendment: 5 
Amendment Date:  29 May 2015 
 
The purpose of this amendment is to (1) extend the ‘maintenance’ dosing treatment period by adding 4 doses of 12 mg equivalent of ISIS 396443 given every 4 months (i.e., on 
Study Days 883, 1009, 1135, and 1261); (2) add the Hammersmith Functional Motor Scale-Expanded as an outcomes measure for al l subjects who have maintained a CHOP INTEND 
total score of ≥ 50 for two consecutive study visits; (3) a dd a ready-to-use vial  configuration of 
the Study Drug; (4) add language on the possibility  to perform an interim analysis to support 
potential discussions with regul atory agencies.  The following table provides a summary list of 
changes to the protocol: 
Section Description of Change Justification 
Protocol Synopsis  
2.4 Rationale for Dose and 
Schedule of Administration  
3. Experimental Plan  
6. Study Procedures  
Appendix A  
Appendix C Maintenance dosing extended to add 
4 additional doses of 12 mg equivalent 
of ISIS 396443 given once every 
4 months.  Additional telephone 
contact assessments (approximately 
once every 3 weeks) have been added 
to accommodate the extension of the 
treatment period. Due to the severe, life-threatening nature of infantile-onset SMA, and 
the encouraging risk-benefit profile 
of ISIS 396443 observed in this 
patient population in early parts of 
the study, the treatment duration is 
being extended (including 
additional study visit and 
telephone contact assessments). 
2.3.4 Clinical Experience  Update clinical section with respect to Phase 2 study status. This section was updated to list all ongoing studies. 
Protocol Synopsis  
6.2 Study Assessments 
10.1.3 Exploratory Endpoints  
13. References  
Appendix A  Hammersmith Functional Motor Scale 
Expanded (HFMSE) was added as an 
exploratory endpoint for subjects who 
have maintained a CHOP INTEND 
total score of ≥ 50 for two consecutive 
study visits.  Two (2) references on the HFMSE were added. The HFMSE is added to allow 
capturing functional improvements 
seen in stronger infants who have 
started to reach t he ceiling of the 
CHOP INTEND. 
Protocol Synopsis  
7. Study Drug 
8.1 Study Drug Administration  Added information on the two types of 
Study Drug supply:  (1) a two-vial configuration in whic h Study Drug is at 
a concentration of 20 mg/mL which is 
diluted prior to use, and (2) a ready-to-
use vial configuration in which the 
Study Drug is at a concentration of 
2.4 mg/mL. As the study progresses, the 
transition will be made from the two-vial configuration to the ready-
to-use vial configuration for ease of administration. 
Protocol Synopsis  
10.4 Interim Analysis Added language to allow for an interim 
analysis. The possibility to perform an interim analysis was added to support potential discussions with 
regulatory agencies. 
  
 
 
ISIS PHARMACEUTICALS, INC. 
 
 
ISIS  396443-CS3A  
 
A Study to Assess the Safety, Tolerability , and Pharmacokinetics of 
Multiple Doses of ISIS  396443 Delivered Intrathecally to Patients 
with Infantile -Onset Spinal Muscular Atrophy  
 
Amendment 4  – 19 May  2014 
 
  
 
 
Sponsor:  
Isis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad, CA  92010 

PPD
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 4   
Protocol   19 May 2014  
 
3   
ISIS  396443  
Isis Protocol Number ISIS  396443- CS3A 
Protocol Amendment 4  
 
Clinical Phase:   2 
A Study to Assess the Safety, Tolerability , and Pharmacokinetics of 
Multiple Doses of ISIS  396443 Delivered Intrathecally to Patients 
with Infantile -Onset Spinal Muscular Atrophy  
 
Trial Sponsor:  Isis Pharmaceuticals,  Inc. 
2855 Gazelle Court  
Carlsbad, CA  92010  
Phone:  + 01 760 931 9200  
Fax: + 01 760 603 2700  
Key Sponsor Contact:  
 
 
Phone:  +  
Fax: +  
  
Date:  19 May 2014  
 
 
Confidentiality Statement 
This document contains confidential information of Isis Pharmaceuticals, Inc.  that must not be 
disclosed to anyone other than the recipient study staff and members of the institutional review 
board or authorized r egulatory agencies.  This information cannot be used for any purpose other 
than the evaluation or conduct of the clinical investigation without the prior written consent of 
Isis Pharmaceuticals, Inc.  
PPD
PPD
PPD
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 4   
Protocol   19 May 2014  
 
4  Protocol  Signature Page 
 
Protocol Number:  ISIS 396443- CS3A 
Protocol Title:  A Study to Assess the Safety, Tolerability , and Pharmacokinetics  of 
Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients with 
Infantile -Onset Spinal Muscular Atrophy 
Amendment:  Amendment 4 
Date:  19 May  2014  
 
I hereby acknowledge that I have read and understand the attached clinical protocol, entitled “ A 
Study to Assess the Safety, Tolerability , and Pharmacokinetics  of Multiple Doses of ISIS 396443 
Delivered Intrathecally to Patients with Infantile -Onset Spinal Muscular Atrophy” , dated 
19 May  2014, and agree to conduct the study as described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline on 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Isis Pharmaceuticals, Inc.   
 
 
 
   
Investigator’s Signature  
   
Investigator’s Name (please print)   Date (DD Month YYYY)  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 4   
Protocol   19 May 2014  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENT .......................................................................................................9  
PROTOCOL SYNOPSIS  ............................................................................................................10  
STUDY GLOSSARY ...................................................................................................................14  
1. OBJECTIVES  .....................................................................................................................16  
1.1 Primary Objective  .....................................................................................................16  
1.2 Secondary Objective  .................................................................................................16  
1.3 Exploratory Objective ...............................................................................................16  
2. BACKGROUND AND RATIO NALE  ..............................................................................16  
2.1 Spinal Muscular Atrophy ..........................................................................................16  
2.2 Therapeutic Rationale  ...............................................................................................17  
2.3 ISIS 396443 ..............................................................................................................18  
2.3.1  Mechan ism of Action  ...............................................................................18  
2.3.2  Chemistry  .................................................................................................18  
2.3.3  Preclinical Experience  ..............................................................................18  
2.3.4  Clinical Experience ..................................................................................19  
2.4 Rationale for Dose and Schedule of Administration ................................................20  
3. EXPERIMENTAL PLAN ..................................................................................................20  
3.1 Study Design  .............................................................................................................20  
3.2 Number of Study Centers..........................................................................................21  
3.3 Number of Subjects...................................................................................................21  
3.4 Overall Study Duration and Follow-up.....................................................................21  
3.4.1  Screening  ..................................................................................................21  
3.4.2  Treatment  ..................................................................................................21  
3.4.3  Post- Treatment Follow -up ........................................................................22  
3.5 End of Study .............................................................................................................22  
3.6 Safety Monitoring and Dose Escalation  ...................................................................22  
3.7 Dose Limiting Toxicity  .............................................................................................22  
4. SUBJECT ENROLLMENT ...............................................................................................23  
4.1 Screening ...................................................................................................................23  
4.2 Registration ...............................................................................................................23  
4.3 Replacement of Subjects  ...........................................................................................23  
5. SUBJECT ELIGIBILITY  ..................................................................................................23  
5.1 Inclusion Criteria  ......................................................................................................23  
5.2 Exclusion Criteria  .....................................................................................................24  
6. STUDY PROCEDURES  ....................................................................................................25  
6.1 Study Schedule..........................................................................................................25  
6.2 Study Assessments  ....................................................................................................25  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 4   
Protocol   19 May 2014  
 
6  6.2.1  Collection of CSF .....................................................................................25  
6.2.2  Laboratory Analytes  .................................................................................25  
6.2.3  Neurological Examinations  ......................................................................25  
6.2.4  Pharmacokinetics Specimen Collection  ...................................................25  
6.2.5  Children’s Hospital of Philadelphia Infant Test for Neuromuscular 
Disease (CHOP  INTEND)  .......................................................................26  
6.2.6  Compound Muscle Action Potential ........................................................26  
6.2.7  Growth Parameters  ...................................................................................26  
6.2.8  Ventilation Use  .........................................................................................26  
6.2.9  Phone Assessments ...................................................................................26  
6.2.10  Safety Evaluations  ....................................................................................27  
7. STUDY DRUG  ....................................................................................................................27  
7.1 Study Drug and Diluent Description.........................................................................27  
7.2 Packaging and Labeling  ............................................................................................27  
7.3 Study Drug Accountability .......................................................................................28  
8. TREATMENT OF SUBJECTS .........................................................................................28  
8.1 Study Drug Administration  .......................................................................................28  
8.2 Other Protocol- Required Drugs  ................................................................................29  
8.3 Other Protocol- Required Procedures  ........................................................................29  
8.4 Treatment Precautions  ..............................................................................................29  
8.5 Safety Monitoring Rules ...........................................................................................29  
8.6 Stopping Rules ..........................................................................................................29  
8.7 Adjustment of Dose and/or Treatment Schedule  ......................................................29  
8.8 Discontinuation of Study Treatment .........................................................................30  
8.9 Withdrawal of Subjects from the Study ....................................................................30  
8.10  Concomitant Therapy and Procedures ......................................................................31  
8.10.1  Concomitant Therapy ...............................................................................31  
8.10.2  Concomitant Procedures ...........................................................................31  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................31  
9.1 Sponsor Review of Safety Information.....................................................................31  
9.2 Regulatory Requirements ..........................................................................................31  
9.3 Definitions .................................................................................................................32  
9.3.1  Adverse Event  ..........................................................................................32  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ................................32  
9.3.3  Serious Adverse Event (SAE) ..................................................................32  
9.4 Monitoring and Recording Adverse Events ..............................................................33  
9.4.1  Serious Adverse Events ............................................................................33  
9.4.2  Non-Serious Adverse Events ....................................................................33  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ......................33  
9.4.3.1  Relationship to the Study Drug ...................................................33  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 4   
Protocol   19 May 2014  
 
7  9.4.3.2  Severity  .......................................................................................34  
9.4.3.3  Action Taken with Study Drug ...................................................34  
9.4.3.4  Treatment Given for Adverse Event  ...........................................34  
9.4.3.5  Outcome of the Adverse Event ...................................................34  
9.5 Procedures for Handling Special Situations .............................................................35  
9.5.1  Abnormalities of Laboratory Tests ...........................................................35  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled 
Treatments  ................................................................................................35  
9.5.3  Dosing Errors ...........................................................................................36  
10. STATISTICAL CONSIDERATIONS  ..............................................................................36  
10.1  Study Endpoints  ........................................................................................................36  
10.1.1  Primary Endpoint .....................................................................................36  
10.1.2  Secondary Endpoint .................................................................................36  
10.1.3  Exploratory Endpoints ..............................................................................37  
10.2  Sample Size Considerations ......................................................................................37  
10.3  Populations ................................................................................................................37  
10.4  Interim Analysis  ........................................................................................................37  
10.5  Planned Methods of Analysis ...................................................................................37  
10.5.1  Demographic and Baseline Characteristics  ..............................................37  
10.5.2  Safety and Tolerability  .............................................................................37  
10.5.3  Pharmacokinetic Analysis  ........................................................................38  
10.5.4  Exploratory Biomarker and Efficacy Analysis ........................................38  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .................................................38  
11.1  Informed Consent......................................................................................................38  
11.2  Ethical Conduct of the Study ....................................................................................39  
11.3  Institutional Review Board/Research Ethics Board  ..................................................39  
11.4  Subject Confidentiality  .............................................................................................39  
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  ....................................................40  
12.1  Protocol Amendments ...............................................................................................40  
12.2  Study Termination  ....................................................................................................40  
12.3  Study Documentation and Storage ............................................................................40  
12.4  Study Monitoring ......................................................................................................41  
12.5  Language  ...................................................................................................................41  
12.6  Compensation for Injury ...........................................................................................41  
13. REFERENCES  ....................................................................................................................42  
14. APPENDICES  .....................................................................................................................44  
Appendix A  Schedule of Procedures ..............................................................................45  
Appendix B  Laboratory Analytes ...................................................................................49  
Appendix C  Pharmacokinetic Sampling Schedule .........................................................51  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 4   
Protocol   19 May 2014  
 
8  TABLE OF TABLES 
Page 
Table 1  Study Drug Characteristics  ................................................................................... 27  
Table 2  ISIS 396443 Dose Equivalents and Concentration During the ‘Loading’ 
Dosing Treatment Period  ...................................................................................... 28  
Table 3  ISIS 396443 Dose Equivalent and Concentration During the 
‘Maintenance’ Dosing Treatment Period  .............................................................. 28  
Table 4  ISIS 396443 Dose Volume to be Injected ............................................................. 29  
 
 
TABLE OF FIGURES 
Page 
Figure 1  ASO Therapeutic Approach for Treatment of SMA  ............................................. 17  
 
  
ISIS 396443-CS3A CONFIDENTIAL Amendment 4
Protocol 19 May 2014
 
9  PROTOCOL AMENDMENT 
 
Protocol Number:  ISIS 396443-CS3A 
Protocol Title: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of 
Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients with Infantile-Onset Spinal Muscular Atrophy
 
Amendment: 4 
Amendment Date:  19 May 2014 
 
The purpose of this amendment is to exte nd maintenance dosing with ISIS 396443 by adding 
4 additional doses of 12 mg equivalent give n every 4 months (i.e., on Study Days 379, 505, 631, 
and 757).   
The following table provides a summary list of changes to the protocol: 
Section Description of Change Justification 
Protocol Synopsis ,  
3. Experimental Plan ,  
6.2 Study Procedures ,  
8. Treatment of Subjects 
Appendix A ,  
Appendix C Maintenance dosing extended to add 
4 additional doses of 12 mg equivalent 
of ISIS 396443 given once every 
4 months Due to the severe, life-threatening nature of infantile-onset SMA, and 
the encouraging risk-benefit profile 
of ISIS 396443 observed in this 
patient population in the early part of the study, the treatment 
duration is being extended 
2.3.3 Preclinical Experience  Detailed results of preclinical studies replaced with a summary statement 
and the relevant sections of the 
Investigator Brochure are referenced Investigator Brochure has been updated with results of the long-
term toxicology study in juvenile 
monkeys 
2.4 Rationale for Dose and  
Schedule of 
Administration  Rationale for loading and maintenance 
dose and regimen has been updated  Dose and dosing regimen selection have been justified on 
the basis of available clinical and 
preclinical PK data 
8.1 Study Drug Administration  Row added for study drug injection volume in subjects >24 months of age Necessary to accommodate extension of the treatment period 
 
 
 
  
 
 
ISIS PHARMACEUTICALS, INC. 
 
 
ISIS  396443-CS3A  
 
A Study to Assess the Safety, Tolerability , and Pharmacokinetics of 
Multiple Doses of ISIS  396443 Delivered Intrathecally to Patients 
with Infantile -Onset Spinal Muscular Atrophy  
 
Amendment 3  – 14 March  2014 
 
  
 
 
Sponsor:  
Isis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad, CA  92010 

PPD
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 3   
Protocol   14 March  2014  
 
3   
ISIS  396443  
Isis Protocol Number ISIS  396443- CS3A 
Protocol Amendment 3  
 
Clinical Phase:   2 
A Study to Assess the Safety, Tolerability , and Pharmacokinetics of 
Multiple Doses of ISIS  396443 Delivered Intrathecally to Patients 
with Infantile -Onset Spinal Muscular Atrophy  
 
Trial Sponsor:  Isis Pharmaceuticals,  Inc. 
2855 Gazelle Court  
Carlsbad, CA  92010  
Phone:  + 01 760 931 9200  
Fax: + 01 760 603 2700  
Key Sponsor Contact:  
 
 
Phone:  +  
Fax: +  
  
Date:  14 March  2014  
 
 
Confidentiality Statement 
This document contains confidential information of Isis Pharmaceuticals, Inc.  that must not be 
disclosed to anyone other than the recipient study staff and members of the institutional review 
board or authorized r egulatory agencies.  This information cannot be used for any purpose other 
than the evaluation or conduct of the clinical investigation without the prior written consent of 
Isis Pharmaceuticals, Inc.  
PPD
PPD
PPD
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 3   
Protocol   14 March  2014  
 
4  Protocol  Signature Page 
 
Protocol Number:  ISIS 396443- CS3A 
Protocol Title:  A Study to Assess the Safety, Tolerability , and Pharmacokinetics  of 
Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients with 
Infantile -Onset Spinal Muscular Atrophy 
Amendment:  Amendment 3 
Date:  14 March  2014  
 
I hereby acknowledge that I have read and understand the attached clinical protocol, entitled “ A 
Study to Asse ss the Safety, Tolerability , and Pharmacokinetics  of Multiple Doses of ISIS 396443 
Delivered Intrathecally to Patients with Infantile -Onset Spinal Muscular Atrophy” , dated 
14March  2014, and agree to conduct the study as described herein. 
I agree to comply with the International Conference on Harmonization  Tripartite Guideline on 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Isis Pharmaceuticals, Inc.   
 
 
 
   
Investigator’s Signature  
   
Investigator’s Name (please print)   Date (DD Month YYYY)  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 3   
Protocol   14 March  2014  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENT .......................................................................................................9  
PROTOCOL SYNOPSIS  ............................................................................................................10  
STUDY GLOSSARY ...................................................................................................................14  
1. OBJECTIVES  .....................................................................................................................16  
1.1 Primary Objective  .....................................................................................................16  
1.2 Secondary Objective  .................................................................................................16  
1.3 Exploratory Objective ...............................................................................................16  
2. BACKGROUND AND RATIO NALE  ..............................................................................16  
2.1 Spinal Muscular Atrophy ..........................................................................................16  
2.2 Therapeutic Rationale  ...............................................................................................17  
2.3 ISIS 396443 ..............................................................................................................18  
2.3.1  Mechanism of Action  ...............................................................................18  
2.3.2  Chemistry  .................................................................................................18  
2.3.3  Preclinical Experience  ..............................................................................18  
2.3.4  Clinical Experience ..................................................................................19  
2.4 Rationale for Dose and Schedule of Administration ................................................20  
3. EXPERIMENTAL PLAN ..................................................................................................21  
3.1 Study Design  .............................................................................................................21  
3.2 Number of Study Centers..........................................................................................22  
3.3 Number of Subjects...................................................................................................22  
3.4 Overall Study Duration and Follow-up.....................................................................22  
3.4.1  Screening  ..................................................................................................22  
3.4.2  Treatment  ..................................................................................................22  
3.4.3  Post- Treatment Follow -up ........................................................................22  
3.5 End of Study .............................................................................................................22  
3.6 Safety Monitoring and Dose Escalation  ...................................................................23  
3.7 Dose Limiting Toxicity  .............................................................................................23  
4. SUBJECT ENROLLMENT ...............................................................................................23  
4.1 Screenin g...................................................................................................................23  
4.2 Registration  ...............................................................................................................24  
4.3 Replacement of Subjects  ...........................................................................................24  
5. SUBJECT ELIGIBILITY  ..................................................................................................24  
5.1 Inclusion Criteria  ......................................................................................................24  
5.2 Exclusion Criteria  .....................................................................................................25  
6. STUDY PROCEDURES  ....................................................................................................25  
6.1 Study Schedule..........................................................................................................25  
6.2 Study Assessments  ....................................................................................................26  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 3   
Protocol   14 March  2014  
 
6  6.2.1  Collection of CSF .....................................................................................26  
6.2.2  Laboratory Analytes  .................................................................................26  
6.2.3  Neurological Examinations  ......................................................................26  
6.2.4  Pharmacokinetics Specimen Collection  ...................................................26  
6.2.5  Children’s Hospital of Philadelphia Infant Test for Neuromuscular 
Disease (CHOP  INTEND)  .......................................................................27  
6.2.6  Compound Muscle Action Potential ........................................................27  
6.2.7  Growth Parameters  ...................................................................................27  
6.2.8  Ventilation Use  .........................................................................................27  
6.2.9  Phone Assessments ...................................................................................27  
6.2.10  Safety Evaluations  ....................................................................................27  
7. STUDY DRUG  ....................................................................................................................28  
7.1 Study Drug and Diluent Description.........................................................................28  
7.2 Packaging and Labeling  ............................................................................................28  
7.3 Study Drug Accountability .......................................................................................28  
8. TREATMENT OF SUBJECTS .........................................................................................28  
8.1 Study Drug Administration  .......................................................................................28  
8.2 Other Protocol- Required Drugs  ................................................................................30  
8.3 Other Protocol- Required Procedures  ........................................................................30  
8.4 Treat ment Precautions ..............................................................................................30  
8.5 Safety Monitoring Rules ...........................................................................................30  
8.6 Stopping Rules ..........................................................................................................30  
8.7 Adjustment of Dose and/or Treatment Schedule ......................................................30  
8.8 Discontinuation of Study Treatment .........................................................................30  
8.9 Withdrawal of Subjects from the Study  ....................................................................30  
8.10  Concomitant Therapy and Procedures  ......................................................................31  
8.10.1  Concomitant Therapy ...............................................................................31  
8.10.2  Concomitant Procedures ...........................................................................32  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................32  
9.1 Sponsor Review of Safety Information .....................................................................32  
9.2 Regulatory Requirements ..........................................................................................32  
9.3 Definitions .................................................................................................................32  
9.3.1  Adverse Event  ..........................................................................................32  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ................................32  
9.3.3  Serious Adverse Event (SAE) ..................................................................32  
9.4 Monitoring and Recording Adverse Events ..............................................................33  
9.4.1  Serious Adverse Events ............................................................................33  
9.4.2  Non-Serious Adverse Events ....................................................................34  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ......................34  
9.4.3.1  Relationship to th e Study Drug  ...................................................34  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 3   
Protocol   14 March  2014  
 
7  9.4.3.2  Severity  .......................................................................................34  
9.4.3.3  Action Taken with Study Drug ...................................................35  
9.4.3.4  Treatment Given for Adverse Event  ...........................................35  
9.4.3.5  Outcome of the Adverse Event ...................................................35  
9.5 Procedures for Handling Special Situations  .............................................................35  
9.5.1  Abnormalities of Laboratory Tests ...........................................................35  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled 
Treatmen ts ................................................................................................36  
9.5.3  Dosing Errors ...........................................................................................36  
10. STATISTICAL CONSIDERATIONS  ..............................................................................36  
10.1  Study Endpoints  ........................................................................................................36  
10.1.1  Primary Endpoint .....................................................................................36  
10.1.2  Secondary Endpoint .................................................................................37  
10.1.3  Exploratory Endpoints ..............................................................................37  
10.2  Sample Size Considerations ......................................................................................37  
10.3  Populations ................................................................................................................37  
10.4  Interim Analysis  ........................................................................................................38  
10.5  Planned Methods of Analysis ...................................................................................38  
10.5.1  Demographic and Baseline Characteristics  ..............................................38  
10.5.2  Safety and Tolerability  .............................................................................38  
10.5.3  Pharmacokinetic Analysis  ........................................................................38  
10.5.4  Exploratory Biomarker and Efficacy Analysis ........................................38  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .................................................38  
11.1  Informed Cons ent......................................................................................................38  
11.2  Ethical Conduct of the Study ....................................................................................39  
11.3  Institutional Review Board/Research Ethics Board  ..................................................39  
11.4  Subject Confidentiality  .............................................................................................39  
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  ....................................................40  
12.1  Protocol Amendm ents ...............................................................................................40  
12.2  Study Termination  ....................................................................................................40  
12.3  Study Documentation and Storage ............................................................................40  
12.4  Study Monitoring ......................................................................................................41  
12.5  Language  ...................................................................................................................41  
12.6  Compensation for Injury ...........................................................................................42  
13. REFERENCES  ....................................................................................................................43  
14. APPENDICES  .....................................................................................................................45  
Appendix A  Schedule of Procedures ...........................................................................46  
Appendix B  Laboratory Analytes ................................................................................50  
Appendix C  Pharmacokinetic Sampling Schedule ......................................................52  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 3   
Protocol   14 March  2014  
 
8   
TABLE OF TABLES 
Page 
Table 1  Study Drug Characteristics  ................................................................................... 28  
Table 2  ISIS 396443 Dose Equivalents and Concentration During the ‘Loading’ 
Dosing Treatment Period  ...................................................................................... 29  
Table 3  ISIS 396443 Dose Equivalent and Concentration During the 
‘Maintenance’ Dosing Treatment Period  .............................................................. 29  
Table 4  ISIS 396443 Dose Volume to be Injected ............................................................. 29  
 
 
TABLE OF FIGURES 
Page 
Figure 1  ASO Therapeutic Approach for Treatment of SMA  ............................................. 17  
 
  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 3   
Protocol   14 March  2014  
 
9  PROTOCOL AMENDMENT  
 
Protocol Number:  ISIS 396443-CS3A 
Protocol Title:  A Study to Assess the Safety, Tolerability , and Pharmacokinetics  of 
Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients with 
Infantile -Onset Spinal Muscular Atrophy  
Amendment:  3 
Amendment Date:  14 March  2014 
 
The purpose of this amendment is to  add permanent ventilation to the combined efficacy 
endpoint.  The definition of permanent ventilation is ≥ 16 hours ventilation/day continuously for 
>2 weeks in the absence of an acute reversible illness .  This definition is consistent with what 
was done in Natural History Study data in the infantile SMA patient population (PNCR study, 
Finkel et al ., unpublished data).  
The following table provides a summary list of changes to the protocol: 
Section Description of Change  
Synopsis ;  
10.1.3  Exploratory Endpoints  Changed efficacy endpoint to: Age at death or permanent ventilation (defined as ≥16 hours 
ventilation/day  continuously for >2 weeks in the 
absence of an acute reversible illness ), to be 
consistent with natural history study data in the 
infantile SMA population (PNCR study, Finkel et al .). 
 
 
  
 
 
ISIS PHARMACEUTICALS, INC. 
 
 
ISIS  396443-CS3A  
 
A Study to Assess the Safety, Tolerability , and Pharmacokinetics of 
Multiple Doses of ISIS  396443 Delivered Intrathecally to Patients 
with Infantile -Onset Spinal Muscular Atrophy  
 
Amendment 2  – 18 January 2014 
 
  
 
 
Sponsor:  
Isis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad, CA  92010 

PPD
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 2   
Protocol   18 January 2014  
 
3   
ISIS  396443  
Isis Protocol Number ISIS  396443- CS3A 
Protocol Amendment 2  
 
Clinical Phase:   2 
A Study to Assess the Safety, Tolerability , and Pharmacokinetics of 
Multiple Doses of ISIS  396443 Deliv ered Intrathecally to Patients 
with Infantile -Onset Spinal Muscular Atrophy  
 
Trial Sponsor:  Isis Pharmaceuticals,  Inc. 
2855 Gazelle Court  
Carlsbad, CA  92010  
Phone:  + 01 760 931 9200  
Fax: + 01 760 603 2700  
Key Sponsor Contact:  
 
 
Phone:  +  
Fax: +  
  
Date:  18 January 2014 
 
 
Confidentiality Statement 
This document contains confidential information of Isis Pharmaceuticals, Inc.  that must not be 
disclosed to anyone other than the recipient study staff and members of the institutional review 
board or authorized r egulatory agencies.  This information cannot be used for any purpose other 
than the evaluation or conduct of the clinical investigation without the prior written consent of 
Isis Pharmaceuticals, Inc.  
PPD
PPD
PPD
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 2   
Protocol   18 January 2014  
 
4  Protocol  Signature Page 
 
Protocol Number:  ISIS 396443- CS3A 
Protocol Title:  A Study to Assess the Safety, Tolerability , and Pharmacokinetics  of 
Multiple Doses of ISIS 396443 De livered Intrathecally to Patients with 
Infantile -Onset Spinal Muscular Atrophy 
Amendment:  Amendment 2 
Date:  18 January 2014  
 
I hereby acknowledge that I have read and understand the attached clinical protocol, entitled “ A 
Study to Assess the Safety, Tolerability , and Pharmacokinetics  of Multiple Doses of ISIS 396443 
Delivered Intrathecally to Patients with Infantile -Onset Spinal Muscular Atrophy” , dated 18 
January 2014, and agree to conduct the study as described herein. 
I agree to comply with the International Conference on Harmonization  Tripartite Guideline on 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Isis Pharmaceuticals, Inc.   
 
 
 
   
Investigator’s Signature  
   
Investigator’s Name (please print)   Date (DD Month YYYY)  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 2   
Protocol   18 January 2014  
 
5  TABLE OF CONTENTS  
Page 
PROTO COL AMENDMENT .......................................................................................................9  
PROTOCOL SYNOPSIS  ............................................................................................................10  
STUDY GLOSSARY ...................................................................................................................14  
1. OBJECTIVES  .....................................................................................................................16  
1.1 Primary Objective  .....................................................................................................16  
1.2 Secondary Objective  .................................................................................................16  
1.3 Exploratory Objective ...............................................................................................16  
2. BACKGROUND AND RATIO NALE  ..............................................................................16  
2.1 Spinal Muscular Atrophy ..........................................................................................16  
2.2 Therapeutic Rationale  ...............................................................................................17  
2.3 ISIS 396443 ..............................................................................................................18  
2.3.1  Mechanism of Action  ...............................................................................18  
2.3.2  Chemistry  .................................................................................................18  
2.3.3  Preclinical Experience  ..............................................................................18  
2.3.4  Clinical Experience ..................................................................................19  
2.4 Rationale for Dose and Schedule of Administration ................................................20  
3. EXPERIMENTAL PLAN ..................................................................................................21  
3.1 Study Design  .............................................................................................................21  
3.2 Number of Study Centers..........................................................................................22  
3.3 Number of Subjects...................................................................................................22  
3.4 Overall Study Duration and Follow-up.....................................................................22  
3.4.1  Screening  ..................................................................................................22  
3.4.2  Treatment  ..................................................................................................22  
3.4.3  Post- Treatment Follow -up ........................................................................22  
3.5 End of Study .............................................................................................................22  
3.6 Safety Monitoring and Dose Escalat ion ...................................................................23  
3.7 Dose Limiting Toxicity  .............................................................................................23  
4. SUBJECT ENROLLMENT ...............................................................................................23  
4.1 Screening ...................................................................................................................23  
4.2 Registration  ...............................................................................................................24  
4.3 Replacement of Subjects  ...........................................................................................24  
5. SUBJECT ELIGIBILITY  ..................................................................................................24  
5.1 Inclusion Criteria  ......................................................................................................24  
5.2 Exclusion Criteria  .....................................................................................................25  
6. STUDY PROCEDURES  ....................................................................................................25  
6.1 Study Schedule..........................................................................................................25  
6.2 Study Assessments  ....................................................................................................26  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 2   
Protocol   18 January 2014  
 
6  6.2.1  Collection of CSF .....................................................................................26  
6.2.2  Laboratory Analytes  .................................................................................26  
6.2.3  Neurological Examinations  ......................................................................26  
6.2.4  Pharmacokinetics Specimen Collection  ...................................................26  
6.2.5  Children’s Hospital of Philadelphia Infant Test for Neuromuscular 
Disease (CHOP  INTEND)  .......................................................................27  
6.2.6  Compound Muscle Action Potential ........................................................27  
6.2.7  Growth Parameters  ...................................................................................27  
6.2.8  Ventilation Use  .........................................................................................27  
6.2.9  Phone Assessments ...................................................................................27  
6.2.10  Safety Evaluations  ....................................................................................27  
7. STUDY DRUG  ....................................................................................................................28  
7.1 Study Drug and Diluent Description.........................................................................28  
7.2 Packaging and Labeling  ............................................................................................28  
7.3 Study Drug Accountability .......................................................................................28  
8. TREATMENT OF SUBJECTS .........................................................................................28  
8.1 Study Drug Administration  .......................................................................................28  
8.2 Other Protocol- Required Drugs  ................................................................................30  
8.3 Other Protocol- Required Procedures  ........................................................................30  
8.4 Treatment Precautions  ..............................................................................................30  
8.5 Safety Monitoring Rules ...........................................................................................30  
8.6 Stopping Rules ..........................................................................................................30  
8.7 Adjustment of Dose and/or Treatment Schedule ......................................................30  
8.8 Discontinuation of Study Treatment .........................................................................30  
8.9 Withdrawal of Subjects from the Study ....................................................................30  
8.10  Concomitant Therapy and Procedures  ......................................................................31  
8.10.1  Concomitant Therapy ...............................................................................31  
8.10.2  Concomitant Procedures ...........................................................................32  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................32  
9.1 Sponsor Review of Safety Information.....................................................................32  
9.2 Regulatory Requirements ..........................................................................................32  
9.3 Definitions .................................................................................................................32  
9.3.1  Adverse Event  ..........................................................................................32  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ................................32  
9.3.3  Serious Adverse Event (SAE) ..................................................................32  
9.4 Monitoring and Recording Adverse Events ..............................................................33  
9.4.1  Serious Adverse Events ............................................................................33  
9.4.2  Non-Serious Adverse Events ....................................................................34  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ......................34  
9.4.3.1  Relationship to the Study Drug ...................................................34  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 2   
Protocol   18 January 2014  
 
7  9.4.3.2  Severity  .......................................................................................34  
9.4.3.3  Action Taken with Study Drug ...................................................35  
9.4.3.4  Treatment Given for Adverse Event  ...........................................35  
9.4.3.5  Outcome of the Adverse Event ...................................................35  
9.5 Procedures for Handling Special Situations .............................................................35  
9.5.1  Abnormalities of Laboratory Tests ...........................................................35  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled 
Treatments  ................................................................................................36  
9.5.3  Dosing Errors ...........................................................................................36  
10. STATISTICAL CONSIDERATIONS  ..............................................................................36  
10.1  Study Endpoints  ........................................................................................................36  
10.1.1  Primary Endpoint .....................................................................................36  
10.1.2  Secondary Endpoint .................................................................................37  
10.1.3  Exploratory Endpoints ..............................................................................37  
10.2  Sample Size Considerations ......................................................................................37  
10.3  Populations ................................................................................................................37  
10.4  Interim Analysis  ........................................................................................................38  
10.5  Planned Methods of Analysis ...................................................................................38  
10.5.1  Demographic and Baseline Characteristics  ..............................................38  
10.5.2  Safety and Tolerability  .............................................................................38  
10.5.3  Pharmacokinetic Analysis  ........................................................................38  
10.5.4  Exploratory Biomarker and Efficacy Analysis ........................................38  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .................................................38  
11.1  Informed Consent......................................................................................................38  
11.2  Ethical Conduct of the Study ....................................................................................39  
11.3  Institutional Review Board/Research Ethics Board  ..................................................39  
11.4  Subject Confidentiality  .............................................................................................39  
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  ....................................................40  
12.1  Protocol Amendments ...............................................................................................40  
12.2  Study Termination  ....................................................................................................40  
12.3  Study Documentation and Storage ............................................................................40  
12.4  Study Monitoring ......................................................................................................41  
12.5  Language  ...................................................................................................................41  
12.6  Compensation for Injury ...........................................................................................42  
13. REFERENCES  ....................................................................................................................43  
14. APPENDICES  .....................................................................................................................45  
Appendix A  Schedule of Procedures ...........................................................................46  
Appendix B  Laboratory Analytes ................................................................................50  
Appendix C  Pharmacokinetic Sampling Schedule ......................................................52  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 2   
Protocol   18 January 2014  
 
8   
TABLE OF TABLES 
Page 
Table 1  Study Drug Characteristics  ................................................................................... 28  
Table 2  ISIS 396443 Dose Equivalents and Concentration During the ‘Loading’ 
Dosing Treatment Period  ...................................................................................... 29  
Table 3  ISIS 396443 Dose Equivalent and Concentration During the 
‘Maintenance’ Dosing Treatment Period  .............................................................. 29  
Table 4  ISIS 396443 Dose Volume to be Injected ............................................................. 29  
 
 
TABLE OF FIGURES 
Page 
Figure 1  ASO Therapeutic Approach for Treatment o f SMA  ............................................. 17  
 
  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 2   
Protocol   18 January 2014  
 
9  PROTOCOL AMENDMENT  
 
Protocol Number:  ISIS 396443-CS3A 
Protocol Title:  A Study to Assess the Safety, Tolerability , and Pharmacokinetics  of 
Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients with 
Infantile -Onset Spinal Muscular Atrophy  
Amendment:  2 
Amendment Date:  18 January 2014 
 
The purpose of this amendment is to extend the study to add one additional ‘maintenance’ dose 
of 12 mg equivalent ISIS 396443 on Study Day 253, approximately 6 months after the subjects 
have received their Day 85 dose.  A few typographical errors were also corrected for 
consistency. 
The following table provides a summary list of changes to the protocol: 
Section Description of Change  
PROTOCOL SYNOPSIS, Study Design and Methodology  Added ‘maintenance’ dose treatment and follow -up 
to the study  design  
2.4 Rationale for Dose and Schedule of Administration  Added dose rationale for the single ‘maintenance ’ 
dose  
3. EXPERIMENTAL PLAN  Added ‘maintenance’ dose treatment and follow -up 
to the study  design  
6.2 Study Assessments  Added ‘maintenance’ dose treatment and follow -up 
to the study assessments  
8.1 Study Drug Administration  Added study drug administration instructions for the 
‘maintenance’ dose  
8.7 Adjustment of Dose and/or Treat ment Schedule  Added instructions for the  ‘maintenance’ dose 
APPENDIX A  Schedule of Procedures  Added ‘maintenance’ dose treatment and follow -up 
to the schedule of procedures  
APPENDIX C  Pharmacokinetic Schedule  Added pharmacokinetic sample schedule for t he 
‘maintenance’ dose period  
 
 
  
 
 
ISIS PHARMACEUTICALS, INC. 
 
 
ISIS  396443-CS3A  
 
A Study to Assess the Safety, Tolerability , and Pharmacokinetics of 
Multiple Doses of ISIS  396443 Delivered Intrathecally to Patients 
with Infantile -Onset Spinal Muscular Atrophy  
 
Amendment 1  – 14 August  2013 
 
  
 
 
Sponsor:  
Isis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad, CA  92010 

PPD
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 1  
Protocol   14 August  2013  
 
3   
ISIS  396443  
Isis Protocol Number ISIS  396443- CS3A 
Protocol Amendment 1  
 
Clinical Phase:   2 
A Study to Assess the Safety, Tolerability , and Pharmacokinetics of 
Multiple Doses of ISIS  396443 Delivered Intrathecally to Patients 
with Infantile -Onset Spinal Muscular Atrophy  
 
Trial Sponsor:  Isis Pharmaceuticals,  Inc. 
2855 Gazelle Court  
Carlsbad, CA  92010  
Phone:  + 01 760 931 9200  
Fax: + 01 760 603 2700  
Key Sponsor Contact:  
 
 
Phone:  +  
Fax: +  
  
Date:  14 August  2013 
 
 
Confidentiality Statement 
This document contains confidential information of Isis Pharmaceuticals, Inc.  that must not be 
disclosed to anyone other than the recipient study staff and members of the institutional review 
board or authorized r egulatory agencies.  This information cannot be used for any purpose other 
than the evaluation or conduct of the clinical investigation without the prior written consent of 
Isis Pharmaceuticals, Inc.  
PPD
PPD
PPD
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 1  
Protocol   14 August  2013  
 
4  Protocol  Signature Page 
 
Protocol Number:  ISIS 396443- CS3A 
Protocol Title:  A Study to Assess the Safety, Tolerability , and Pharmacokinetics  of 
Multiple Doses of ISIS 396443 Delivered Intrathecally to Patient s with 
Infantile -Onset Spinal Muscular Atrophy 
Amendment:  Amendment 1 
Date:  14 August 2013  
 
I hereby acknowledge that I have read and understand the attached clinical protocol, entitled “ A 
Study to Assess the Safety, Tolerability , and Pharmacokinetics  of M ultiple Doses of ISIS 396443 
Delivered Intrathecally to Patients with Infantile -Onset Spinal Muscular Atrophy” , dated 
14 August 2013, and agree to conduct the study as described herein. 
I agree to comply with the International Conference on Harmonization  Tripartite Guideline on 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written  consent of Isis Pharmaceuticals, Inc.   
 
 
 
   
Investigator’s Signature  
   
Investigator’s Name (please print)   Date (DD Month YYYY)  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 1  
Protocol   14 August  2013  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENT .......................................................................................................9  
PROTOCOL SYNOPSIS  ............................................................................................................10  
STUDY GLOSSARY ...................................................................................................................14  
1. OBJECTIVES  .....................................................................................................................16  
1.1 Primary Objective  .....................................................................................................16  
1.2 Secondary Objective  .................................................................................................16  
1.3 Exploratory Objective ...............................................................................................16  
2. BACKGROUND AND RATIO NALE  ..............................................................................16  
2.1 Spinal Muscular Atrophy ..........................................................................................16  
2.2 Therapeutic Rationale  ...............................................................................................17  
2.3 ISIS 396443 ..............................................................................................................18  
2.3.1  Mechanism of Action  ...............................................................................18  
2.3.2  Chemistry  .................................................................................................18  
2.3.3  Preclinical Experience  ..............................................................................18  
2.3.4  Clinical Experience ..................................................................................19  
2.4 Rationale for Dose and Schedule of Administration ................................................20  
3. EXPERIMENTAL PLAN ..................................................................................................21  
3.1 Study Design  .............................................................................................................21  
3.2 Number of Study Centers..........................................................................................22  
3.3 Number of Subjects...................................................................................................22  
3.4 Overall Stud y Duration and Follow-up.....................................................................22  
3.4.1  Screening  ..................................................................................................22  
3.4.2  Treatment  ..................................................................................................22  
3.4.3  Post- Treatment Follow -up ........................................................................22  
3.5 End of Study .............................................................................................................22  
3.6 Safety Monitoring and Dose Escalation  ...................................................................22  
3.7 Dose Limiting Toxicity  .............................................................................................23  
4. SUBJECT ENROLLMENT ...............................................................................................23  
4.1 Screening ...................................................................................................................23  
4.2 Registration  ...............................................................................................................24  
4.3 Replacement of Subjects  ...........................................................................................24  
5. SUBJECT ELIGIBILITY  ..................................................................................................24  
5.1 Inclusion Criteria  ......................................................................................................24  
5.2 Exclusion Criteria  .....................................................................................................25  
6. STUDY PROCEDURE S ....................................................................................................25  
6.1 Study Schedule..........................................................................................................25  
6.2 Study Assessments  ....................................................................................................25  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 1  
Protocol   14 August  2013  
 
6  6.2.1  Collec tion of CSF .....................................................................................25  
6.2.2  Laboratory Analytes  .................................................................................26  
6.2.3  Neurological Examinations  ......................................................................26  
6.2.4  Pharmacokinetics Specimen Collection  ...................................................26  
6.2.5  Children’s Hospital of Philadelphia Infant Test for Neuromuscular 
Disease (CHOP  INTEND)  ................................................................26  
6.2.6  Compound Muscle Action Potential ........................................................27  
6.2.7  Growth Parameters  ...................................................................................27  
6.2.8  Ventilation Use  .........................................................................................27  
6.2.9  Phone Assessments ...................................................................................27  
6.2.10  Safety Evaluations  ....................................................................................27  
7. STUDY DRUG ....................................................................................................................28  
7.1 Study Drug and Diluent Description.........................................................................28  
7.2 Packaging and Labeling  ............................................................................................28  
7.3 Study Drug Accountability .......................................................................................28  
8. TREATMENT OF SUBJECTS .........................................................................................28  
8.1 Study Drug Administration  .......................................................................................28  
8.2 Other Protocol- Required Drugs  ................................................................................29  
8.3 Other Protocol- Required Procedures  ........................................................................29  
8.4 Treatment Precautions  ..............................................................................................29  
8.5 Safety Monitoring Rules ...........................................................................................29  
8.6 Stopping Rules ..........................................................................................................29  
8.7 Adjustment of Dose and/or Treatment Schedule ......................................................29  
8.8 Discontinuation of Study Treatment .........................................................................30  
8.9 Withdrawal of Subj ects from the Study  ....................................................................30  
8.10  Concomitant Therapy and Procedures  ......................................................................31  
8.10.1  Concomitant Therapy ...............................................................................31  
8.10.2  Concomitant Procedures ...........................................................................31  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ..........................31  
9.1 Spons or Review of Safety Information .....................................................................31  
9.2 Regulatory Requirements ..........................................................................................31  
9.3 Definitions .................................................................................................................32  
9.3.1  Adverse Event  ..........................................................................................32  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ................................32  
9.3.3  Serious Adverse Event (SAE)  ..................................................................32  
9.4 Monitoring and Recording Adverse Events ..............................................................33  
9.4.1  Serious Adverse Events ............................................................................33  
9.4.2  Non-Serious Adverse Events ....................................................................33  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ......................33  
9.4.3.1  Relationship to the Study Drug ...................................................33  
ISIS 396443-CS3A CONFIDENTIAL Amendment 1 
Protocol 14 Augus t2013
 
7  9.4.3.2  Severity .......................................................................................34  
9.4.3.3  Action Taken with Study Drug ...................................................34  
9.4.3.4  Treatment Given for Adverse Event ...........................................34  
9.4.3.5  Outcome of the Adverse Event ...................................................34  
9.5 Procedures for Handling Special Situations .............................................................35  
9.5.1  Abnormalities of Laboratory Tests ...........................................................35  
9.5.2  Prescheduled or Elective Proce dures or Routinely Scheduled  
Treatments ................................................................................................35  
9.5.3  Dosing Errors ...........................................................................................36  
10. STATISTICAL CONSIDERATIONS ..............................................................................36  
10.1 Study Endpoints ........................................................................................................36  
10.1.1 Primary Endpoint .....................................................................................36  
10.1.2 Secondary Endpoint .................................................................................36  
10.1.3 Exploratory Endpoints ..............................................................................36  
10.2 Sample Size Considerations ......................................................................................37  
10.3 Populations ................................................................................................................37  
10.4 Interim Analysis ........................................................................................................37  
10.5 Planned Methods of Analysis ...................................................................................37  
10.5.1 Demographic and Baseline Characteristics ..............................................37  
10.5.2 Safety and Tolerability .............................................................................37  
10.5.3 Pharmacokinetic Analysis ........................................................................38  
10.5.4 Exploratory Biomarker a nd Efficacy Analysis ........................................38  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS .................................................38  
11.1 Informed Consent......................................................................................................38  
11.2 Ethical Conduct of the Study ....................................................................................38  
11.3 Institutional Review Board/ Research Ethics Board ..................................................38  
11.4 Subject Confidentiality .............................................................................................39  
12. ADMINISTRATIVE AND LEGAL OBLIGATIONS ....................................................39  
12.1 Protocol Amendments ...............................................................................................39  
12.2 Study Termination ....................................................................................................39  
12.3 Study Documentation and Storage............................................................................40  
12.4 Study Monitoring ......................................................................................................40  
12.5 Language ...................................................................................................................41  
12.6 Compensation for Injury ...........................................................................................41  
13. REFERENCES .................................................................................................................... 42 
14. APPENDICES .................................................................................................................... .44 
Appendix A  Schedule of Procedures ..............................................................................45  
Appendix B  Laboratory Analytes ...................................................................................48  
Appendix C  Pharmacokinetic Sampling Schedule .........................................................50  
 
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 1  
Protocol   14 August  2013  
 
8  TABLE OF TABLES 
Page 
Table 1  Study Drug Characteristics  ................................................................................... 28  
Table 2  ISIS 396443 Dose Equivalents and Concentration ............................................... 29  
Table 3  ISIS 396443 Dose Volume to be Injected ............................................................. 29  
 
 
TABLE OF FIGURES 
Page 
Figure 1  ASO Therapeutic Approach for Treatment of SMA  ............................................. 17  
 
  
ISIS 396443 -CS3A  CONFIDENTIAL  Amendment 1  
Protocol   14 August  2013  
 
9  PROTOCOL AMENDMENT  
 
Protocol Number:  ISIS 396443-CS3A 
Protocol Title:  A Study to Assess the Safety, Tolerability , and Pharmacokinetics  of 
Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients with 
Infantile -Onset Spinal Muscular Atrophy  
Amendment:  1 
Amendment Date:  14 August 2013 
 
The purpose of this amendment is to: 1) change the dose from 9 to 12 mg ISIS 396443; 2) add 
additional subjects to the study, such that Cohort 2 now may enroll between 4 to approximately 16 subjects; 3) add age at death and age at death or ≥ 16 hours ventilation/ day for >2 weeks as 
exploratory endpoints ; and 4) update the clinical experience section, specifically regarding the 
ISIS 396443-CS2 and ISIS 396443-CS12 studies. 
The following table provides a summary list of changes to the protocol: 
Section Description o f Change  
2.3.4 Clinical Experience  Updated information regarding ISIS 396443-CS2 and 
ISIS 396443-CS12 studies  
2.4 Rationale for Dose and Schedule of  
Administration  Changed “9 mg ISIS 396443” to “12 mg ISIS 396443” 
throughout the section and added rationale for 12 mg 
dose  
3.3 Number of Subjects  For Cohort 2 changed “4” to “4 to approximately 16” 
subjects  to allow additional subjects to enroll in this study 
prior to when the anticipated Phase 3 study in Infantile-
onset SMA commences  
8.1 Study Drug Admini stration  Updated dose and concentration in Table 2 and Table 3 
for 12 mg dosing  
10.2 Sample Size Considerations  Changed “sample size of 8” to “sample size of 
approximately 20”  
10.1.3  Exploratory Endpoints  Added age at death and age at death or ≥16 hours 
ventilation/day for >2 weeks as exploratory endpoints  
 
 